US Pat. No. 10,596,174

PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES

ACEA THERAPEUTICS, INC., ...

1. A method for curative treatment of a proliferation disorder, cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, or dry eye, comprising administering to a subject in need of such treatment an effective amount of N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide or a pharmaceutically acceptable salt thereof.
US Pat. No. 10,597,454

PD-1 ANTIBODIES

INNOVENT BIOLOGICS (SUZHO...

1. An antibody that binds human PD-1 (SEQ ID NO:1), comprising a light chain (LC) and a heavy chain (HC), whereinthe light chain comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3 consisting of the amino acid sequences as set forth by SEQ ID NO:10, SEQ ID NO:11 and SEQ ID NO:12, respectively, and
the heavy chain comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, wherein
HCDR1 consists of the amino acid sequence as set forth by SEQ ID NO:2;
HCDR2 consists of the amino acid sequences as set forth by SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:7; and
HCDR3 consists of the amino acid sequences as set forth by SEQ ID NO:8 or SEQ ID NO:9.
US Pat. No. 10,597,710

LIGASE ACTIVITY

New England Biolabs, Inc....

1. A method for detecting a polymorphism in an RNA, comprising:(a) hybridizing at least two DNA polynucleotide sequences to a polymorphic sequence in an RNA;
(b) ligating the at least two DNA polynucleotide sequences to one another using a ligase that has an amino acid sequence that is at least 90% identical to the Chlorella virus PBCV-1 ligase of SEQ ID NO:1, to produce a ligation product, and
(c) detecting the ligation product of (b), thereby detecting the polymorphic sequence.
US Pat. No. 10,601,041

DOPED LITHIUM POSITIVE ELECTRODE ACTIVE MATERIAL AND PROCESS FOR MANUFACTURE THEREOF

1. A lithium positive electrode active material comprising at least 95 wt % spinel having a chemical composition of LixNiyMn2-y-z1-z2D1z1D2z2O4,wherein 0.9?x?1.1, 0.4?y?0.5, 0.005?z1?0.2, 0?z2?0.2,
wherein D1 and D2 are dopants chosen between the following elements: Co, Cu, Ti, Zn, Mg, Fe or combinations thereof, where D1 and D2 are different dopants,
wherein the lithium positive electrode active material is a powder composed of material particles,
wherein the distribution of dopant D1 is non-uniform along a radial axis of the material particles and wherein the distribution of the dopant D2 is substantially uniform along the radial axis of the material particles.
US Pat. No. 10,596,175

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES

Novartis AG, Basel (CH)

1. A method for treating leishmaniasis, comprising administering to a subject in need thereof a therapeutically effective amount of N-(4-fluoro-3-(6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl)-2,4-dimethyloxazole-5-carboxamide, or a pharmaceutically acceptable salt thereof; and optionally in combination with a second agent.
US Pat. No. 10,597,455

METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASE ASSOCIATED WITH ALPHA-V BETA-8 INTEGRIN

THE REGENTS OF THE UNIVER...

1. An isolated nucleic acid encoding an antibody that specifically binds to human integrin ?8 and inhibits adhesion of latency associated peptide (LAP) to ?v?8, wherein the antibody comprises:a heavy chain variable region comprising the Kabat-determined or Chothia-determined complementarity determining regions (HCDR1, HCDR2, and HCDR3) of SEQ ID NO:1 and a light chain variable region comprising the Kabat-determined or Chothia-determined complementarity determining regions (LCDR1, LCDR2, and LCDR3) of SEQ ID NO:16; or
a heavy chain variable region comprising the Kabat-determined or Chothia-determined complementarity determining regions (HCDR1, HCDR2, and HCDR3) of SEQ ID NO:2 and a light chain variable region comprising the Kabat-determined or Chothia-determined complementarity determining regions (LCDR1, LCDR2, and LCDR3) of SEQ ID NO:16; or
a heavy chain variable region comprising the Kabat-determined or Chothia-determined complementarity determining regions (HCDR1, HCDR2, and HCDR3) of SEQ ID NO:3 and a light chain variable region comprising the Kabat-determined or Chothia-determined complementarity determining regions (LCDR1, LCDR2, and LCDR3) of SEQ ID NO:16; or
a heavy chain variable region comprising the Kabat-determined or Chothia-determined complementarity determining regions (HCDR1, HCDR2, and HCDR3) of SEQ ID NO:4 and a light chain variable region comprising the Kabat-determined or Chothia-determined complementarity determining regions (LCDR1, LCDR2, and LCDR3) of SEQ ID NO:16; or
a heavy chain variable region comprising the Kabat-determined or Chothia-determined complementarity determining regions (HCDR1, HCDR2, and HCDR3) of SEQ ID NO:5 and a light chain variable region comprising the Kabat-determined or Chothia-determined complementarity determining regions (LCDR1, LCDR2, and LCDR3) of SEQ ID NO:16; or
a heavy chain variable region comprising the Kabat-determined or Chothia-determined complementarity determining regions (HCDR1, HCDR2, and HCDR3) of SEQ ID NO:6 and a light chain variable region comprising the Kabat-determined or Chothia-determined complementarity determining regions (LCDR1, LCDR2, and LCDR3) of SEQ ID NO:16; or
a heavy chain variable region comprising the Kabat-determined or Chothia-determined complementarity determining regions (HCDR1, HCDR2, and HCDR3) of SEQ ID NO:7 and a light chain variable region comprising the Kabat-determined or Chothia-determined complementarity determining regions (LCDR1, LCDR2, and LCDR3) of SEQ ID NO:17; or
a heavy chain variable region comprising the Kabat-determined or Chothia-determined complementarity determining regions (HCDR1, HCDR2, and HCDR3) of SEQ ID NO:8 and a light chain variable region comprising the Kabat-determined or Chothia-determined complementarity determining regions (LCDR1, LCDR2, and LCDR3) of SEQ ID NO:18; or
a heavy chain variable region comprising the Kabat-determined or Chothia-determined complementarity determining regions (HCDR1, HCDR2, and HCDR3) of SEQ ID NO:9 and a light chain variable region comprising the Kabat-determined or Chothia-determined complementarity determining regions (LCDR1, LCDR2, and LCDR3) of SEQ ID NO:19; or
a heavy chain variable region comprising the Kabat-determined or Chothia-determined complementarity determining regions (HCDR1, HCDR2, and HCDR3) of SEQ ID NO:10 and a light chain variable region comprising the Kabat-determined or Chothia-determined complementarity determining regions (LCDR1, LCDR2, and LCDR3) of SEQ ID NO:20; or
a heavy chain variable region comprising the Kabat-determined or Chothia-determined complementarity determining regions (HCDR1, HCDR2, and HCDR3) of SEQ ID NO:11 and a light chain variable region comprising the Kabat-determined or Chothia-determined complementarity determining regions (LCDR1, LCDR2, and LCDR3) of SEQ ID NO:20; or
a heavy chain variable region comprising the Kabat-determined or Chothia-determined complementarity determining regions (HCDR1, HCDR2, and HCDR3) of SEQ ID NO:12 and a light chain variable region comprising the Kabat-determined or Chothia-determined complementarity determining regions (LCDR1, LCDR2, and LCDR3) of SEQ ID NO:20; or
a heavy chain variable region comprising the Kabat-determined or Chothia-determined complementarity determining regions (HCDR1, HCDR2, and HCDR3) of SEQ ID NO:13 and a light chain variable region comprising the Kabat-determined or Chothia-determined complementarity determining regions (LCDR1, LCDR2, and LCDR3) of SEQ ID NO:20; or
a heavy chain variable region comprising the Kabat-determined or Chothia-determined complementarity determining regions (HCDR1, HCDR2, and HCDR3) of SEQ ID NO:14 and a light chain variable region comprising the Kabat-determined or Chothia-determined complementarity determining regions (LCDR1, LCDR2, and LCDR3) of SEQ ID NO:21; or
a heavy chain variable region comprising the Kabat-determined or Chothia-determined complementarity determining regions (HCDR1, HCDR2, and HCDR3) of SEQ ID NO:15 and a light chain variable region comprising the complementarity determining regions (LCDR1, LCDR2, and LCDR3) of SEQ ID NO:22.
US Pat. No. 10,597,711

PHASE-PROTECTING REAGENT FLOW ORDERINGS FOR USE IN SEQUENCING-BY-SYNTHESIS

LIFE TECHNOLOGIES CORPORA...

1. A method for nucleic acid sequencing, comprising:disposing a plurality of template polynucleotide strands, sequencing primers, and polymerases in a plurality of defined spaces of a sensor array;
exposing the plurality of template polynucleotide strands to a series of flows of nucleotide species, the series comprising a combinatorial ordering of flows comprising a plurality of different adjacent 4-flow permutations of different nucleotide species A, C, G, and T, wherein adjacent 4-flow permutations in the combinatorial ordering of flows differ by a single transposition of two nucleotide species; and
obtaining, for each of the series of flows of nucleotide species, a signal indicative of how many nucleotide incorporations occurred for that particular flow to determine a predicted sequence of nucleotides corresponding to the plurality of template polynucleotide strands.
US Pat. No. 10,601,042

SECONDARY BATTERY POSITIVE ELECTRODE ACTIVE MATERIAL AND METHOD FOR PRODUCING SAME

TAIHEIYO CEMENT CORPORATI...

1. A positive electrode active substance, whereina water-insoluble electrically conductive carbon material comprising graphite and carbon obtained by carbonizing glucose are supported on a compound comprising iron or manganese, wherein the compound is represented by formula (A), (B), or (C):
LiFeaMnbM1cPO4  (A)
wherein M1 represents Mg, Ca, Sr, Y, Zr, Mo, Ba, Pb, Bi, La, Ce, Nd, or Gd, and a, b, and c each represent a number satisfying 0.01?a?1, 0.01?b?1, 0?c?0.2, and 2a+2b+(valence of M1)×c=2;
Li2FedMneM2fSiO4  (B)
wherein M2 represents Ni, Co, Al, Zn, V, or Zr, and d, e, and f each represent a number satisfying 0?d?1, 0?e?1, 0?f<1, 2d+2e+(valence of M2)×f=2, and d+e?0; and
NaFegMnhQiPO4  (C)
wherein Q represents Mg, Ca, Co, Sr, Y, Zr, Mo, Ba, Pb, Bi, La, Ce, Nd, or Gd, and g, h, and i each represent a number satisfying 0?g?1, 0.5?h?1, and 0?i<1, 2g+2h+(valence of Q)×i=2;
wherein if the compound is represented by Formula (A) or (C), an amount of the graphite and the carbon derived from glucose in terms of carbon atoms is a total of from 3.0 to 12.0 mass %, and wherein an amount of carbon derived from glucose is 0.5 to 8.0 mass %; and
wherein if the compound is represented by Formula (B), an amount of the graphite and the carbon derived from glucose in terms of carbon atoms is a total of from 4.0 to 15.0 mass %, and an amount of carbon derived from glucose is 0.75 to 10.0 mass %.
US Pat. No. 10,596,176

METHODS TO TREAT VISUAL IMPAIRMENT

Massachusetts Institute o...

1. A method of treating amblyopia in a subject, the method comprising performing retinal inactivation in both retinas of the subject, wherein the retinal inactivation is performed by administering an anesthetic.
US Pat. No. 10,597,456

CHIMERIC RECEPTORS AND METHODS OF USE THEREOF

AMGEN INC., Thousand Oak...

1. A chimeric antigen receptor that binds to C-type lectin-like-1 (“CLL-1”), wherein the chimeric antigen receptor is a polypeptide comprising a single chain Fv (scFv) that binds CLL-1, a transmembrane domain, and an intracellular activating domain that is a signaling domain of CD3 zeta, and wherein the scFv comprises a heavy chain variable region (VH) and light chain variable region (VL) pair that is selected from the group consisting of:(a) a VH region comprising complementarity determining regions (“CDRs”) 1, 2, and 3 with amino acid sequences SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19, respectively, and a VL region comprising CDRs 1, 2, and 3 with amino acid sequences SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24, respectively;
(b) a VH region comprising CDRs 1, 2, and 3 with amino acid sequences SEQ ID NO: 51, SEQ ID NO: 52, and SEQ ID NO: 53, respectively, and a VL region comprising CDRs 1, 2, and 3 with amino acid sequences SEQ ID NO: 56, SEQ ID NO: 57, and SEQ ID NO: 58, respectively;
(c) a VH region comprising CDRs 1, 2, and 3 with amino acid sequences SEQ ID NO: 73, SEQ ID NO: 74, and SEQ ID NO: 75, respectively, and a VL region comprising CDRs 1, 2, and 3 with amino acid sequences SEQ ID NO: 78, SEQ ID NO: 79, and SEQ ID NO: 80, respectively; and
(d) a VH region comprising CDRs 1, 2, and 3 with amino acid sequences SEQ ID NO: 95, SEQ ID NO: 96, and SEQ ID NO: 97, respectively, and a VL region comprising CDRs 1, 2, and 3 with amino acid sequences SEQ ID NO: 100, SEQ ID NO: 101, and SEQ ID NO: 102, respectively.
US Pat. No. 10,596,177

COMBINATIONS OF AN FGFR INHIBITOR AND AN IGF1R INHIBITOR

ASTEX THERAPEUTICS LTD, ...

1. A combination of a FGFR inhibitor and an IGF1R inhibitor, wherein the FGFR inhibitor is N-(3,5-dimethoxyphenyl)-N?-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine or a pharmaceutically acceptable salt thereof or a solvate thereof, and the IGF1R inhibitor is selected from GSK1838705A and BMS-754807.
US Pat. No. 10,597,713

HAIRPIN LOOP METHOD FOR DOUBLE STRAND POLYNUCLEOTIDE SEQUENCING USING TRANSMEMBRANE PORES

Oxford Nanopore Technolog...

1. A method for nanopore sensing, the method comprising:i) coupling a nucleic acid construct transiently to a membrane via a 3? cholesterol TEG tether,
wherein the membrane comprises an amphiphilic layer that is a 1,2-diphytanoyl-glycero-3-phosphocholine lipid bilayer, and wherein a MspA transmembrane pore is present in the membrane, wherein the MspA transmembrane pore is a nanopore, and is configured to permit flow of ions through the transmembrane pore from one side of the membrane to the other side of the membrane,
wherein the construct comprises a target polynucleotide having a target portion, a leader, and the 3? cholesterol TEG tether, wherein the construct is configured such that the leader facilitates engagement of the construct with the transmembrane pore while the construct is transiently coupled to the membrane, promoting passage of the nucleic acid construct through the nanopore, and
wherein the step of transiently coupling the construct to the membrane comprises contacting the membrane with the construct, wherein the construct comprises, prior to the contacting step, the target polynucleotide, the leader, and the 3? cholesterol TEG tether; and
ii) sensing at least the target portion of the target polynucleotide upon movement of the construct through the nanopore, wherein sensing comprises reading nucleotides of the nucleic acid construct as the nucleotides pass through the nanopore in order to sequence the target portion, wherein the nucleotides are read from single channel currents obtained from electrodes connected to a buffered solution on cis and trans sides of the lipid bilayer comprising the nanopore.
US Pat. No. 10,596,178

TABLET FORMULATION OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YLMETHYL) IMIDAZO [1,2-B] [1,2,4] TRIAZIN-2-YL] BENZAMIDE

Novartis AG, Basel (CH)

1. A tablet comprising 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, or a pharmaceutically acceptable salt thereof, wherein the tablet comprises:(a) an intragranular phase comprising, by weight, about:
23.54% of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide dihydrochloric acid salt,
20% of mannitol,
20.26% of microcrystalline cellulose,
0.2% of sodium dodecyl sulfate,
5% of polyvinylpolypyrrolidone, and
4% of polyvinylpyrrolidone; and
(b) an extragranular phase comprising, by weight, about:
20.75% of microcrystalline cellulose,
0.5% of colloidal silicon dioxide,
5% of polyvinylpolypyrrolidone, and
0.75% of magnesium stearate;
wherein the percentages given for the respective ingredients are relative to the total weight of the tablet.
US Pat. No. 10,597,458

ANTI-CD25 ANTIBODY AGENTS

Tusk Therapeutics Ltd., ...

1. An antibody or antigen-binding fragment comprising:a) aCD25-a-674-HCDR3amino acid sequence (SEQ ID NO: 4) as variable heavy chain complementarity determining region 3;
b) aCD25-a-674-HCDR2amino acid sequence (SEQ ID NO: 3) as variable heavy chain complementarity determining region 2;
c) aCD25-a-674-HCDR1amino acid sequence (SEQ ID NO: 2) as variable heavy chain complementarity determining region 1;
d) aCD25-a-674-LCDR1amino acid sequence (SEQ ID NO: 6) as variable light chain complementarity determining region 1;
e) aCD25-a-674-LCDR2amino acid sequence (SEQ ID NO: 7) as variable light chain complementarity determining region 2; and
f) aCD25-a-674-LCDR3amino acid sequence (SEQ ID NO: 8) as variable light chain complementarity determining region 3.
US Pat. No. 10,597,459

ANTI-CD25 ANTIBODY AGENTS

Tusk Therapeutics Ltd., ...

1. An antibody or antigen-binding fragment thereof, comprising:a) aCD25-a-686-HCDR3 amino acid sequence (SEQ ID NO: 4) as variable heavy chain complementarity determining region 3;
b) aCD25-a-686-HCDR1 amino acid sequence (SEQ ID NO: 2) as variable heavy chain complementarity determining region 1;
c) aCD25-a-686-HCDR2 amino acid sequence (SEQ ID NO: 3) as variable heavy chain complementarity determining region 2;
d) aCD25-a-686-LCDR1 amino acid sequence (SEQ ID NO: 6) as variable light chain complementarity determining region 1;
e) aCD25-a-686-LCDR2 amino acid sequence (SEQ ID NO: 7) as variable light chain complementarity determining region 2; and
f) aCD25-a-686-LCDR3 amino acid sequence (SEQ ID NO: 8) as variable light chain complementarity determining region 3.
US Pat. No. 10,597,715

METHODS FOR SEQUENCING NUCLEIC ACIDS

Centrillion Technology Ho...

1. A method for sequencing a template nucleic acid molecule, comprising:(a) contacting a stretched and primed template nucleic acid molecule with a substrate, the primed template nucleic acid molecule comprising one or more primer-binding sites, the substrate comprising primers immobilized thereon,
each primer comprising:
(i) a region complementary to a primer-binding site, and
(ii) a barcode sequence indicative of a physical position of the primer on the substrate;
(b) conducting extension reactions using the primers and the template nucleic acid molecule as a template, thereby generating extension products, each extension product comprises (i) sequence of a fragment of the template nucleic acid or complement of the fragment, and (ii) sequence of the barcode sequence or a complement thereof;
(c) sequencing the extension products to determine sequences of the fragments or complements thereof and barcode sequences or complements thereof; and
(d) assembling the sequences of the fragments using the barcode sequence to thereby determine sequence of the template nucleic acid molecule.
US Pat. No. 10,597,460

ANTI-CD40 ANTIBODIES

AbbVie Biotherapeutics In...

1. An anti-human CD40 antibody which is an IgG antibody consisting of heavy chains each consisting of the amino acid sequence of SEQ ID NO:132 and light chains each consisting of the amino acid sequence of SEQ ID NO:141.
US Pat. No. 10,597,716

DEVICE FOR NUCLEIC ACID SEQUENCING

STMICROELECTRONICS S.R.L....

1. A device for sequencing a nucleic acid strand, comprising:a plurality of wells, wherein each well houses:
a solution containing truncated strands extending between a respective first end and a respective second end and having lengths different from one another, wherein the second end terminates with a respective dideoxynucleotide from among ddATP, ddTTP, ddGTP, and ddCTP;
first masses, coupled to the first end of each truncated strand, and functionalized with a donor molecule;
second masses, functionalized for binding only to a respective terminal dideoxynucleotide of the second end of each strand, and functionalized with an acceptor molecule,
wherein the donor molecule and the acceptor molecule are configured to emit light radiation when the donor module is spaced a distance from the acceptor molecule, the distance being shorter than a minimum distance;
an electrical-field generator configured to generate an AC electrical field having a frequency and an amplitude to impress, on each second mass, a net movement directed towards the first mass to which each of the second masses is coupled via said truncated strand;
control means for controlling the electrical-field generator, configured to vary the frequency value in a predefined frequency range;
reading means, configured to acquire a plurality of light radiations emitted by each well at respective frequency values in said range; and
analysis means, configured to associate each light radiation acquired to a respective dideoxynucleotide and, thus, to a respective nucleotide base.
US Pat. No. 10,596,181

TREATMENT OF DEMYELINATING DISEASES

M ET P PHARMA AG, Emmett...

1. A method of promoting remyelination in a subject in need thereof, comprising administering to the subject an effective amount of a steroid hormone and a Hedgehog signaling pathway modulator.
US Pat. No. 10,597,461

SACCHARIDE-BASED BIOMARKERS AND THERAPEUTICS

1. An isolated monoclonal antibody, which antibody specifically binds to an epitope comprising N-acetylglucosamine and specifically binds to an epitope comprising N-acetyl-galactosamine, wherein the epitope is expressed by a cancer cell or an inflammatory cell, and wherein the antibody comprises:(a) a heavy chain variable region comprising three HVRs from the amino acid sequence of SEQ ID NO:1, and a light chain variable region comprising three HVRs from the amino acid sequence of SEQ ID NO:2;
(b) a heavy chain variable region comprising three HVRs from the amino acid sequence of SEQ ID NO:3, and a light chain variable region comprising three HVRs from the amino acid sequence of SEQ ID NO:4;
(c) a heavy chain variable region comprising three HVRs from the amino acid sequence of SEQ ID NO:5, and a light chain variable region comprising three HVRs from the amino acid sequence of SEQ ID NO:6;
(d) a heavy chain variable region comprising an HVR-H1 sequence of SEQ ID NO: 24, an HVR-H2 sequence of SEQ ID NO: 25, and an HVR-H3 sequence of SEQ ID NO: 26; and a light chain variable region comprising an HVR-L1 sequence of SEQ ID NO: 27, an HVR-L2 sequence of SEQ ID NO: 28, and an HVR-L3 sequence of SEQ ID NO: 29;
(e) a heavy chain variable region comprising an HVR-H1 sequence of SEQ ID NO: 7, an HVR-H2 sequence of SEQ ID NO: 30, and an HVR-H3 sequence of SEQ ID NO: 31; and a light chain variable region comprising an HVR-L1 sequence of SEQ ID NO: 11, an HVR-L2 sequence of SEQ ID NO: 14, and an HVR-L3 sequence of SEQ ID NO: 15;
(f) a heavy chain variable region comprising an HVR-H1 sequence of SEQ ID NO: 32, an HVR-H2 sequence of SEQ ID NO: 33, and an HVR-H3 sequence of SEQ ID NO: 34; and a light chain variable region comprising an HVR-L1 sequence of SEQ ID NO: 35, an HVR-L2 sequence of SEQ ID NO: 36, and an HVR-L3 sequence of SEQ ID NO: 37;
(g) a heavy chain variable region comprising an HVR-H1 sequence of SEQ ID NO: 7, an HVR-H2 sequence of SEQ ID NO: 8, and an HVR-H3 sequence of SEQ ID NO: 9; and a light chain variable region comprising an HVR-L1 sequence of SEQ ID NO: 10, an HVR-L2 sequence of SEQ ID NO: 12, and an HVR-L3 sequence of SEQ ID NO: 15;
(h) a heavy chain variable region comprising an HVR-H1 sequence of SEQ ID NO: 7, an HVR-H2 sequence of SEQ ID NO: 8, and an HVR-H3 sequence of SEQ ID NO: 9; and a light chain variable region comprising an HVR-L1 sequence of SEQ ID NO: 11, an HVR-L2 sequence of SEQ ID NO: 13, and an HVR-L3 sequence of SEQ ID NO: 15; or
(i) a heavy chain variable region comprising an HVR-H1 sequence of SEQ ID NO: 7, an HVR-H2 sequence of SEQ ID NO: 8, and an HVR-H3 sequence of SEQ ID NO: 9; and a light chain variable region comprising an HVR-L1 sequence of SEQ ID NO: 11, an HVR-L2 sequence of SEQ ID NO: 14, and an HVR-L3 sequence of SEQ ID NO: 15.
US Pat. No. 10,597,717

COMBINATORIAL DNA SCREENING

1. A method for treating a patient with a tumor therapy, the method comprisingdetermining a tumor fraction associated with a solid tumor of the patient, wherein determining the tumor fraction comprises
(a) screening genomic DNA from the solid tumor to identify a set of somatic mutations;
(b) identifying a subset of the somatic mutations to create a signature panel of mutations specific to the solid tumor, wherein the identification of the subset of the somatic mutations is based on a comparison of the screened genomic DNA from the solid tumor to genomic DNA from non-tumorigenic tissue; and
(c) screening a fluid sample of the patient for the signature panel of mutations, wherein the screening comprises sequencing DNA from the fluid sample, the fluid sample comprising cell free DNA, and wherein sequence reads obtained from the sequencing are used to ascertain the proportion of circulating tumor DNA in the fluid sample comprising cell free DNA from the patient, thereby determining the tumor fraction in the patient;
determining, based on the tumor fraction, a presence of the solid tumor in the patient; and,
in response to determining the presence of the solid tumor in the patient, administering a tumor therapy to the patient.
US Pat. No. 10,596,182

METHODS FOR THE SEPARATION AND DETECTION OF AN OXYSTEROL

Warsaw Orthopedic, Inc., ...

1. A method for determining the amount of OXY133 monohydrate in a sample, the method comprising: providing an OXY133 monohydrate reference standard having a known quantity of OXY133 monohydrate measurable by HPLC-CAD; providing Ma a sample having an unknown quantity of the OXY133 monohydrate; separating the amount of the OXY133 monohydrate in the sample by HPLC-CAD configured with a C18 column with dimensions 4.6×150 mm and a particle size of 3.5 microns; and determining the amount of the OXY133 monohydrate in the sample.
US Pat. No. 10,597,462

ANTI-TLT-1 ANTIBODY AND USES THEREOF

University of Puerto Rico...

1. An anti-TLT-1 antibody, or antigen-binding fragment, comprising the following six hypervariable regions (HVRs):an HVR-H1 comprising the amino acid sequence of (SEQ ID NO: 1);
an HVR-H2 comprising the amino acid sequence of (SEQ ID NO: 2);
an HVR-H3 comprising the amino acid sequence of (SEQ ID NO: 3);
an HVR-L1 comprising the amino acid sequence of (SEQ ID NO: 4);
an HVR-L2 comprising the amino acid sequence of (SEQ ID NO: 5); and
an HVR-L3 comprising the amino acid sequence of (SEQ ID NO: 6).
US Pat. No. 10,597,718

METHODS AND SYSTEMS FOR SAMPLE PROCESSING POLYNUCLEOTIDES

10X GENOMICS, INC., Plea...

1. A method for bead formation, comprising:(a) providing a mixture comprising a plurality of bead precursor molecules and a plurality of nucleic acid molecules, wherein a nucleic acid molecule of said plurality of nucleic acid molecules comprises an adapter sequence, which adapter sequence is configured for compatibility with a nucleic acid sequencer; and
(b) in said mixture, causing linkages to form between (i) a bead precursor molecule of said plurality of bead precursor molecules and an additional bead precursor molecule of said plurality of bead precursor molecules, and (ii) said bead precursor molecule and said nucleic acid molecule of said plurality of nucleic acid molecules.
US Pat. No. 10,596,183

PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASES

ZHEJIANG DTRM BIOPHARMA C...

1. A pharmaceutical composition comprisinga Bruton tyrosine kinase (BTK) inhibitor, wherein the BTK inhibitor is Compound 3 as shown in Table 1, or an enantiomer, a diastereomer, a pharmaceutically acceptable salt, or a prodrug thereof,
a mammalian target of rapamycin (mTOR) kinase inhibitor, wherein the mTOR kinase inhibitor is everolimus or rapamycin, or a pharmaceutically acceptable salt thereof, and
a pharmaceutically acceptable carrier.
US Pat. No. 10,597,463

ANTIBODIES AND MOLECULES DERIVED THEREFROM THAT BIND TO STEAP-1 PROTEINS

AGENSYS, INC., Santa Mon...

1. A monoclonal antibody, or an antigen-binding fragment thereof, that binds to the STEAP-1 protein of SEQ ID NO:3 wherein the antibody, or antigen-binding fragment thereof, comprises all heavy and light chain complementarity determining regions (CDRs) from the antibody designated X92.1.30.1.1(1) (ATCC Accession No.: PTA-5802).
US Pat. No. 10,597,719

DETECTION KIT AND SIMPLE METHOD FOR DETECTING TARGET NUCLEIC ACIDS

National University Corpo...

1. A nucleic acid detection kit comprising:(i) a single-stranded circular DNA template containing:
a sequence of 10 to 30 bases complementary to a first portion of a target nucleic acid; and
a primer-binding sequence of 7 to 8 bases adjacent to 5?-side thereof; and
(ii) an oligonucleotide primer containing:
a sequence of 8 to 15 bases complementary to a second portion adjacent to the 3?-side of the first portion of the target nucleic acid; and
a sequence of 7 to 8 bases adjacent to the 3?-side thereof and complementary to the primer-binding sequence of the single-stranded circular DNA template.
US Pat. No. 10,597,464

HETERODIMERIC ANTIBODY FC-CONTAINING PROTEINS AND METHODS FOR PRODUCTION THEREOF

1. A heterodimeric antibody obtained or obtainable by a method comprising the following steps:a) providing a first nucleic-acid construct encoding a first chimeric, humanized, or human heavy chain comprising a first Fc region, said first Fc region comprising a first CH3 region of human IgG1, but with an amino acid substitution at position 405 (numbering according to the EU Index),
b) providing a second nucleic-acid construct encoding a second chimeric, humanized, or human heavy chain comprising a second Fc region, said second Fc region comprising a first CH3 region of human IgG1, but with an amino acid substitution at position 409 (numbering according to the EU Index),
wherein the heterodimeric antibody does not bind to c-Met and/or EGFR,
c) co-expressing said first and second nucleic-acid constructs in a host cell, and
d) obtaining said heterodimeric antibody from the cell culture.
US Pat. No. 10,597,720

APPARATUS, KITS AND METHODS FOR THE PREDICTION OF ONSET OF SEPSIS

The Secretary of State fo...

1. A diagnostic kit for predicting development of sepsis prior to onset of symptoms, comprising reagents for detecting nucleic acid gene products or expression levels of members of a biomarker signature consisting of 266 genes of Table 1 in a sample obtained from a patient at a risk of sepsis,wherein the reagents comprise one or more of fluorescently labelled oligonucleotide probes or fluorescently labeled primers,
wherein the fluorescently labelled oligonucleotide probes or fluorescently labeled primers consist of probes and primers each capable of specific binding and detection of gene products of at least 25 of the members of the biomarker signature,
and wherein the at least 25 of the members of the biomarker signature comprise ACTR6, BIN1, C16ORF7, CD247, CLNS1A, CYB561, FCER1A, GRB10, HS.445036, LARP5, LOC646766, MRPL50, ADRB2, BOAT, C21ORF7, CD3D, CPA3, DHRS3, FLT3LG, GTPBP8, ICAM2, LDHA, LOC652071, MRPS27 and AKR1B1.
US Pat. No. 10,596,185

FLAVONOID COMPOSITIONS AND USES THEREOF

INGREDIENTS BY NATURE, M...

1. A method of reducing blood glucose levels in a human subject in need thereof, comprising administering to the subject a composition comprising 100-200 mg eriocitrin once per day.
US Pat. No. 10,597,465

METHODS FOR THE GENERATION OF MULTISPECIFIC AND MULTIVALENT ANTIBODIES

NovImmune SA, Geneva (CH...

1. A method to generate an antibody mixture comprising three or more monospecific antibodies and three or more bispecific antibodies, all having a common heavy chain, the method comprising:a. isolating an antibody or antibody fragment region having a specificity determined by a heavy chain variable domain combined with a first light chain variable domain;
b. isolating several antibodies or antibody fragments region having a different specificity determined by the same heavy chain variable domain as the antibody of step a) combined with different light chain variable domains;
c. co-expressing in a cell:
i. a heavy chain polypeptide comprising the common heavy chain variable domain fused to an immunoglobulin heavy chain constant region;
ii. light chain polypeptides comprising all the light chains of the antibodies isolated in step a) and b) fused either to a light chain constant domain of the Kappa type or fused to a light chain constant domain of the Lambda type; and
d. recovering the heavy chain polypeptide and the light chain polypeptides, thereby generating an antibody mixture comprising three or more monospecific antibodies and three or more bispecific antibodies, all having a common heavy chain.
US Pat. No. 10,597,721

METHODS AND COMPOSITIONS FOR SCREENING AND TREATING DEVELOPMENTAL DISORDERS

POPULATION BIO, INC., Me...

1. A method of hybridizing a nucleic acid probe or synthesizing a nucleic acid product comprising:(a) hybridizing a nucleic acid probe to a polynucleic acid by nucleic acid hybridization or microarray analysis, or synthesizing a nucleic acid product from a polynucleic acid by PCR or sequencing wherein the polynucleic acid is from a sample from a human subject that has Autism Spectrum Disorder (ASD); and
(b) detecting a genetic variation in (i) the polynucleic acid by nucleic acid hybridization or microarray analysis or (ii) the nucleic acid product by PCR or sequencing, wherein the genetic variation is a copy number variant (CNV), wherein the CNV is a gain of SEQ ID NO. 595, or a complement thereof.
US Pat. No. 10,601,052

REVERSIBLE FUEL CELL OXYGEN ELECTRODE, REVERSIBLI FUEL CELL INCLUDING THE SAME, AND METHOD FOR PREPARING THE SAME

Korea Institute of Scienc...

1. A reversible fuel cell oxygen electrode comprising:a porous carbon material;
IrO2 formed on a surface of the porous carbon material; and
platinum formed on the IrO2,
wherein the IrO2 formed on the surface of the porous carbon comprises an IrO2 layer or an IrO2 layer having IrO2 particles attached,
the platinum comprises a porous platinum layer formed on the IrO2 layer of the IrO2 layer having the IrO2 particles attached, and
the electrode has macropores due to the porous carbon material and micropores due to the porous platinum layer.
US Pat. No. 10,596,186

METHOD AND COMPOSITIONS FOR TREATING VIRAL INFECTIONS

PHOENIX BIOTECHNOLOGY, IN...

1. A method of treating viral infection, caused by Filovirus, Ebolavirus or Marburgvirus, in a subject in need thereof, the method comprising administering to the subject one or more doses of an antiviral composition comprising a combination of oleandrin and at least two triterpenes selected from the group consisting of oleanolic acid (free acid, salt or prodrug thereof), ursolic acid (free acid, salt or prodrug thereof), and betulinic acid (free acid, salt or prodrug thereof).
US Pat. No. 10,597,722

PREDICTIVE ANALYSIS FOR MYOCARDIAL INFARCTION

SCRIPPS HEALTH, San Dieg...

1. A method of treating a human individual at increased risk of experiencing a myocardial infarction (MI), comprising:treating a human individual having increased risk of experiencing an MI with a treatment regimen to decrease risk of thrombus formation, the human individual having no detectable necrosis of cardiomyocytes, and identified as having increased risk of experiencing MI by
(i) having an expression level of mRNA transcripts of genes HBEGF, NR4A2, NR4A3, NFKBIA, SYTL3, SULF1, and RNASE1 that is elevated compared to a control or standard derived from a healthy human individual or population of healthy human individuals; or
(ii) having an expression level of mRNA transcripts of genes NR4A2, NR4A3, NFKBIA, SYTL3, SULF1, and RNASE1, that is elevated compared to the control or standard from a diseased human individual or population of diseased human individuals with known but stable cardiovascular disease.
US Pat. No. 10,597,723

METHODS FOR SIMULTANEOUS AMPLIFICATION OF TARGET LOCI

Natera, Inc., San Carlos...

1. A method of amplifying target loci in a nucleic acid sample, the method comprising:(a) contacting a nucleic acid sample comprising target loci with a library of test primers comprising at least 1,000 different primer pairs to produce a reaction mixture in one reaction volume; wherein each primer pair includes a forward test primer and a reverse test primer that hybridize to the same target locus, and wherein the primers do not include molecular inversion probes (MIPs);
(b) subjecting the reaction mixture to PCR conditions to produce amplified products comprising target amplicons; wherein the concentration of each test primer is less than 10 nM; wherein the length of the annealing step of the reaction conditions is greater than 10 minutes; wherein at least 1,000 different target loci are simultaneously amplified; and wherein (i) less than 20% of the amplified products are test primer dimers, (ii) at least 80% of the amplified products are target amplicons, and (iii) at least 80% of the target loci are amplified; and
(c) sequencing the amplified products.
US Pat. No. 10,596,188

USE OF NITRITE SALTS IN TREATING TISSUE DAMAGE

Board of Supervisors of L...

1. A method of treating peripheral neuropathy in a mammalian subject, the method comprising:a) identifying a mammalian subject who has peripheral neuropathy; and
b) administering to the mammalian subject a pharmaceutical composition comprising one of sodium nitrite, potassium nitrite, calcium nitrite, or some combination thereof,wherein the pharmaceutical composition is administered one of intraperitoneally, intravenously, subcutaneously, intramuscularly, sublingually, or orally;the amount of sodium nitrite, potassium nitrite, calcium nitrite, or some combination thereof is a dose of about 0.5 ?g/kg to about 5000 ?g/kg and;the pharmaceutical composition is administered until a cytokine profile generated from a tissue from the mammalian subject is found to be reduced to a level found in normal conditions for the tissue of the mammalian subject, the cytokine profile being at least one of TGF?, IFN?, or IL-17 and wherein the tissue is at or near the site of the peripheral neuropathy.
US Pat. No. 10,597,468

METHODS AND COMPOSITIONS FOR CURING A SURFACE OF AN UNCURED POLYSULFIDE RUBBER

The Boeing Company, Chic...

1. A composition comprising at least about 85% by weight of liquid carrier based on the weight of the composition, a polysulfide rubber curing agent, a metal cation, and an ionic liquid, wherein the liquid carrier is a C1-C3 alcohol, fluorocarbon, aromatic hydrocarbon, hydrofluorocarbon, fluoroketone, or mixture thereof.
US Pat. No. 10,597,724

SYSTEM AND METHOD FOR CLEANING NOISY GENETIC DATA FROM TARGET INDIVIDUALS USING GENETIC DATA FROM GENETICALLY RELATED INDIVIDUALS

Natera, Inc., San Carlos...

1. A method for determining genetic data for DNA from a first individual in a biological sample of a second individual, the method comprising:amplifying a plurality of polymorphic loci on cell-free DNA extracted from the biological sample to generate amplified products;
measuring an amount of the amplified products by sequencing-by-synthesis to obtain genetic data at the plurality of polymorphic loci;
determining the most likely genetic data for DNA from the first individual based on allele frequencies in the genetic data at the plurality of polymorphic loci.
US Pat. No. 10,596,189

EMULSION AND METHOD FOR THE MANUFACTURE THEREOF

BLUE SEA LABORATORIES, S....

1. An emulsion, wherein it contains a mixture of an aqueous phase and an oil phase, wherein the aqueous phase comprises seawater, at least one viscosifier, and at least one humectant, and wherein the oil phase comprises polyglyceryl, hectorite, propylenecarbonate, t-butyl alcohol, polyacrylate crosspolymer-6, at least one viscosifier, at least one emulsifier, at least one co-emulsifier, and at least one emollient, and wherein the emulsion is stabilized, homogenous and without phase separation.
US Pat. No. 10,597,469

METHOD FOR RECOVERING ETHYLENE AND VINYL-BASED COMONOMER

LG Chem, Ltd., (KR)

1. A method for recovering ethylene and a vinyl-based comonomer, comprising:a polymerization step of polymerizing ethylene and a vinyl-based comonomer at a pressure of 1500 bar or more;
a step of depressurizing a product obtained in the polymerization step including an ethylene-vinyl-based comonomer polymer, ethylene, and a vinyl-based comonomer to 0.1 bar to 5 bar;
a step of adding ethylene to the product obtained in the polymerization step under a pressure of 0.1 bar to 5 bar; and
a step of separating ethylene and vinyl-based comonomer from the product obtained in the polymerization step to which ethylene is added.
US Pat. No. 10,598,237

METHOD OF MANUFACTURING BRAKE DISC OF HETEROGENEOUS MATERIALS AND BRAKE DISC OF HETEROGENEOUS MATERIALS MANUFACTURED USING THE SAME

1. A method of manufacturing a brake disc of heterogeneous materials, including a disc device and a hub device formed in a cast-bonding manner using different materials, the method comprising:performing a first casting for casting the disc device using a grey cast-iron material;
performing a preparation step by placing the disc device in a casting mold as an insert;
performing a second casting for preparing a brake disc cast product by injecting molten aluminum alloy into the casting mold and casting the hub device to be cast-bonded to the disc device; and
performing an oxynitriding process for forming an oxynitride layer by smoothing a surface of the brake disc cast product and performing a heat treatment in a gaseous atmosphere at a temperature ranging from 425 to 500° C.
US Pat. No. 10,596,190

METHOD FOR REDUCING OTOTOXICITY IN PEDIATRIC PATIENTS RECEIVING PLATINUM-BASED CHEMOTHERAPY

1. A method of reducing ototoxicity in a pediatric patient of about 5 years of age and under, comprising: administering:(I) cisplatin to treat a localized and non-metastatic tumor at a dose of about 1 mg/kg to about 5 mg/kg or about 10 mg/m2 to about 300 mg/m2 per cycle, administered on between about 1 and 5 days per cycle; and
(II) sodium thiosulfate, at a dose of about 5 g/m2 to about 25 g/m2 given after each dose of the cisplatin on between about 1 and 5 days per cycle, about six hours after the administration of the cisplatin,wherein the reduction of ototoxicity is at least 50% better than a patient not receiving an administration of sodium thiosulfate;wherein ototoxicity is determined by one or more criteria selected from:a) a reduction in hearing measured by a 20 dB loss at a single frequency;b) a reduction in hearing measured by a 10 dB loss at two consecutive frequencies;c) loss of response at three consecutive test frequencies where responses were previously obtained;d) a reduction in bilateral high-frequency hearing characterized by the criteria:i) a <40 dB hearing loss at all frequencies, which indicates a grade 0 or minimal hearing loss;
ii) a ?40 dB hearing loss at 8,000 Hz only, which indicates a grade 1 or mild hearing loss;
iii) a ?40 dB hearing loss at 4,000 Hz and above, which indicates a grade 2 or moderate hearing loss;
iv) a ?40 dB hearing loss at 2,000 Hz and above, which indicates a grade 3 or marked hearing loss;
v) a ?40 dB hearing loss at 1,000 Hz and above, which indicates a grade 4 or severe hearing loss; ore) a reduction in hearing characterized by the criteria:i) a ?20 dB hearing loss at all frequencies, which indicates a grade 0 hearing loss;
ii) a >20 dB HL above 4,000 Hz, which indicates a grade 1 hearing loss;
iii) a >20 dB HL at 4,000 Hz and above, which indicates a grade 2 hearing loss;
iv) a >20 dB HL at 2,000 Hz or 3,000 Hz, which indicates a grade 3 hearing loss;
v) a >40 dB HL at 2,000 Hz and above, which indicates a grade 1 hearing loss;wherein a change in hearing is computed relative to baseline measures prior to the patient receiving a platinum based chemotherapeutic or sodium thiosulfate or both; andwherein the administration of sodium thiosulfate does not substantively affect relapse free survival or overall survival compared to a pediatric patient not administered sodium thiosulfate.
US Pat. No. 10,597,726

BREAST CANCER DETECTION KIT OR DEVICE, AND DETECTION METHOD

TORAY INDUSTRIES, INC., ...

1. A method for detecting breast cancer, comprising determining expression level(s) of hsa-miR-4783-3p in a sample comprising blood, serum, or plasma from a human subject using a kit comprising a nucleic acid(s), as a primer(s) for PCR, or a probe(s) for Northern blot, Southern blot, or in situ hybridization, capable of specifically binding to hsa-miR-4783-3p, wherein the determining comprises the following steps of:(a) contacting hsa-miR-4783-3p in the sample or complementary polynucleotide(s) thereof prepared from hsa-miR-4783-3p with the nucleic acid(s);
(b) measuring an expression level of hsa-miR-4783-3p by quantitative RT-PCR using the nucleic acid(s) as the primer(s), or Northern blot, Southern blot, or in situ hybridization using the nucleic acids as the probe(s); and
(c) comparing the expression level of hsa-miR-4783-3p measured in the step (b) with a control expression level of hsa-miR-4783-3p in a control sample of a healthy subject measured in the same way as in the step (b),
wherein a lower expression level of hsa-miR-4783-3p in the sample comprising blood, serum, or plasma from the subject as compared to the control expression level is detected and is indicative that the subject has breast cancer, and
treating the subject for breast cancer or performing a diagnostic procedure on the subject, wherein the treatment comprises surgery, radiotherapy, chemotherapy or a combination thereof, and wherein the diagnostic procedure comprises mammography, ultrasonography (echo examination), CT, MRI, abdominal ultrasonography, bone scintigraphy, PET, pathological examination of breast tissue or the combination thereof.
US Pat. No. 10,597,471

COLORED PARTICLE DISPERSION

KAO CORPORATION, Tokyo (...

1. A colored fine particle dispersion comprising colored fine particles and a neutralizing agent, in whichthe colored fine particles are produced by subjecting a monomer mixture comprising an acid group-containing polymerizable monomer to emulsion polymerization in the presence of a pigment;
the pigment is a pigment subjected to no hydrophilic treatment;
the acid group is a carboxy group;
the acid group-containing-polymerizable monomer is at least one monomer selected from the group consisting of (meth)acrylic acid, maleic acid, itaconic acid furmaric acid and crotonic acid;
a content of the acid group-containing polymerizable monomer in the monomer mixture is not less than 1% by mass and not more than 20% by mass;
the neutralizing agent comprises a water-soluble amine compound;
a content of the water-soluble amine compound in the neutralizing agent is not less than 80% by mass;
the acid group is neutralized with the water-soluble amine compound; and
the colored fine particle dispersion has a pH value of not less than 6 and not more than 11.
US Pat. No. 10,597,727

STOMACH CANCER DETECTION KIT OR DEVICE, AND DETECTION METHOD

TORAY INDUSTRIES, INC., ...

1. A method for detecting stomach cancer comprising:determining an expression level(s) of hsa-miR-4257 in a sample comprising blood, serum, or plasma from a human subject using a kit comprising a nucleic acid(s), as a primer(s) for PCR, or a probe(s) for Northern blot, Southern blot, or in situ hybridization, capable of specifically binding to hsa-miR-4257, wherein the determining comprises the following steps of:
(a) contacting hsa-miR-4257 in the sample or complementary polynucleotide(s) thereof prepared from hsa-miR-4257 with the nucleic acid(s);
(b) measuring an expression level of hsa-miR-4257 by quantitative RT-PCR using the nucleic acid(s) as the primer(s), or Northern blot, Southern blot, or in situ hybridization using the nucleic acids as the probe(s); and
(c) comparing the expression level of hsa-miR-4257 measured in the step (b) with a control expression level of hsa-miR-4257 in a control sample from a healthy subject measured in the same way as in the step (b), wherein a lower expression level of hsa-miR-4257 in the sample comprising blood, serum, or plasma from the subject as compared to the control expression level is detected and is indicative that the subject has stomach cancer, and
treating the subject for stomach cancer or performing a diagnostic procedure on the subject, wherein the treatment comprises surgery, radiotherapy, chemotherapy, or a combination thereof, and wherein the diagnostic procedure comprises gastric X-ray examination, gastroscopy, or imaging of the stomach.
US Pat. No. 10,596,192

TREATING ROTATOR CUFF CONDITIONS

Mayo Foundation for Medic...

1. A method for treating a mammal having a rotator cuff condition, wherein said method comprising administering a composition comprising N,N,N?,N?-tetrakis-(2-pyridylmethyl) ethylenediamine into a rotator cuff region of said mammal, wherein administration of said composition reduces or reverses tendon degeneration, enhances tendon healing, or increases tendon strength.
US Pat. No. 10,597,728

METHYLATION SITE REGULATING EXPRESSION OF MDA-9/SYNTENIN

VIRGINIA COMMONWEALTH UNI...

1. A method of treating cancer in a subject in need thereof, comprisingi) measuring a level of CpG methylation at cg17197774 in a tumor sample from the subject; and
ii) detecting a level of CpG methylation below a reference value; and
(iii) treating the subject with one or more of surgical debulking, chemotherapy, radiation therapy, or adjunct immunotherapy; wherein one or more of dose, frequency, and duration of treatment is greater than indicated for a subject having a level of tumor CpG methylation at cg17197774 above the reference value.
US Pat. No. 10,598,240

THERMOSETTING RESIN COMPOSITION, FRICTION MATERIAL AND METHOD FOR PRODUCING THERMOSETTING RESIN COMPOSITION

AKEBONO BRAKE INDUSTRY CO...

1. A thermosetting resin composition comprising:a lignin obtained by decomposing a lignocellulose;
a lignocellulose fiber obtained by decomposing the lignocellulose; and
a phenol resin,
wherein after the lignocellulose is decomposed, the lignin and the lignocellulose fiber obtained therefrom are dispersed in the phenol resin, and
wherein a content of the lignocellulose fiber is 1 to 20% by mass.
US Pat. No. 10,596,193

COPPER (I) COMPLEXES WITH GLYCINE, PYRUVATE, AND SUCCINATE

C Lab Pharma Internationa...

1. A method of synthesizing a copper (I) complex comprising:a) charging a salt selected from the group consisting of: a glycinate salt, a pyruvate salt, and a succinate salt, under a stream of inert gas in an alcohol or water;
b) heating the salt in the alcohol or water at about 40-45° C.;
c) adding a copper (I) salt to the alcohol or water and allowing to reflux for at least 12 hours to produce a copper (I) complex;
d) evaporating the alcohol or water from the copper (I) complex.
US Pat. No. 10,597,729

USE OF GENE EXPRESSION PROFILING TO PREDICT SURVIVAL IN CANCER PATIENT

BIOVENTURES, LLC, Little...

1. A detection method comprising:obtaining an isolated nucleic acid sample from plasma cells isolated from a multiple myeloma patient; and
measuring gene expression levels of GNG10, PNPLA4, KIAA1754, AHCYL1, MCLC, EVI5, AD-020, PARG1, CTBS, FUCA1, RFP2, FLJ20489, LTBP1, TRIP13, AIM2, SELI, SLC19A1, LARS2, OPN3, ASPM, CCT2, UBE21, SIK6, FLJ13052, FLJ12525, BIRC5, CKS1B, CKAP1, MGC57827, DKFZp7790175, PFN1, ILF3, IF116, TBRG4, PAPD1, EIF2C2, MGC4308, ENO1, DSG2, EXOSC4, 7AGLN2, RUVBL1, ALDOA, CPSF3, MGC15606, LGALS1, RADI8, SNX5, PSMD4, RAN, KIF14, CBX3, TMPO, DKFZP586L0724, WEE1, ROBO1, TCOF1, YWHAZ, and MPHOSPH1 in the plasma cells by contacting the isolated nucleic acid sample with nucleic acid probes that hybridize to each gene and detecting the complex formed between the plasma cell RNA and each probe, wherein the method comprises detecting reduced expression of GNG10, PNPLA4, KIAA1754, AHCYL1, MCLC, EVI5, AD-020, PARG1, CTBS, FUCA1, RFP2, FLJ20489, or LTBP1, relative to a control from a patient having a favorable prognosis, or detecting increased expression of TRIP13, AIM2, SELI, SLC19A1, LARS2, OPN3, ASPM, CCT2, UBE21, STK6, FLJ13052, FLJ12525, BIRC5, CKS1B, CKAP1, MGC57827, DKFZp7790175, PFN1, ILF3, IFI16, TBRG4, PAPD1, EIF2C2, MGC4308, EN1L, DSG2, EXOSC4, TAGLN2, RUVBL1, ALDOA, CPSF3, MGC15606, LGALS1, RAD18, SNX5, PSMD4, RAN, KIF14, CBX3, TMPO, DKFZP586L0724, WEE1, ROBO1, TCOF1, YWHAZ, or MPHOSPH1, relative to a control from a patient having a favorable prognosis.
US Pat. No. 10,597,730

METHOD OF DIAGNOSING CANCER

The Hospital for Sick Chi...

1. A method of diagnosing cancer, predicting tumour progression from benign to malignant, predicting the grade of a tumour, or predicting survival in a human, said method comprising the steps of:i) determining in a nucleic acid sample from the human the degree of DNA methylation of CG sites within the TERT promoter to yield a sample methylation signature, wherein the sample is optionally amplified and the degree of methylation is determined by sequencing using PCR and/or sequencing primers comprising at least 15 nucleotides which target a nucleotide region of the TERT promoter that is free of CG sites selected from the nucleotide regions: ?142 to ?156, ?231 to ?262, ?292 to ?314, ?345 to ?404 or ?592 to ?615 of the TERT promoter;
ii) determining the baseline degree of DNA methylation of the TERT promoter in a control sample to yield a control methylation signature; and
iii) comparing the sample methylation signature to the control methylation signature and diagnosing cancer, identifying a tumour to be a malignant tumour, or predicting a 5-10 year overall survival or progression-free survival of less than 50% when there is at least 1.5 times more methylation in the sample methylation signature in a region of the hTERT promoter consisting of from the nucleotide at about position ?157 to the nucleotide at about position ?580 as compared to the control methylation signature.
US Pat. No. 10,596,195

DISCOVERY OF REGULATORY T CELLS PROGRAMMED TO SUPPRESS AN IMMUNE RESPONSE

Dana-Farber Cancer Instit...

1. A method for treating an autoimmune disease in a subject comprising:a. isolating and enriching T cells from the subject in need of such treatment to provide a T cell population, wherein at least 10% of the T cell population are CD44+CD122+Kir+CD8??+ Treg cells; and
b. administering the T cell population containing the at least 10% CD44+CD122+Kir+CD8??+ Treg cells to the subject in an amount effective to ameliorate a symptom of the autoimmune disease.
US Pat. No. 10,597,475

POLYMERS CONTAINING S-VINYLTHIO ALKANOLS

BASF SE, Ludwigshafen (D...

1. A polymer containing S-vinyl-2-thioethan-1-ol and acrylic acid wherein no further monomers are used.
US Pat. No. 10,597,731

ALLOGENEIC AUTOPHAGOSOME-ENRICHED COMPOSITION FOR THE TREATMENT OF DISEASE

UbiVac, LLC, Portland, O...

1. A method for detecting an anti-cancer immune response in a mammal, comprising:isolating peripheral blood mononuclear cells from the mammal following an administration of one or more immunotherapeutic compositions to the mammal;
contacting a subpopulation of the isolated peripheral blood mononuclear cells with an enriched population of autophagosomes derived from a cell line, the enriched population of autophagosomes including:
one or more toll-like receptor agonists;
one or more tumor antigens; and
one or more damage-associated molecular pattern molecules; and
determining a level of IFN-? production by the contacted subpopulation of the isolated peripheral blood mononuclear cells.
US Pat. No. 10,596,196

PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST HEAD AND NECK SQUAMOUS CELL CARCINOMA AND OTHER CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. A method of treating cancer in a HLA-A*02+ patient, wherein said cancer comprises cancer cells that overexpress KRT5 and present at their surface in complex with an MHC class I molecule a peptide consisting of the amino acid sequence STASAITPSV (SEQ ID NO: 9), said method comprising administering to said patient an effective amount of activated antigen-specific CD8+ cytotoxic T cells to kill the cancer cells, wherein said activated antigen-specific CD8+ cytotoxic T cells are produced by contacting in vitro CD8+ cytotoxic T cells with an antigen presenting cell presenting at its surface in complex with an MHC class I molecule a peptide consisting of the amino acid sequence STASAITPSV (SEQ ID NO: 9), wherein said cancer is selected from head and neck cancer, esophageal cancer, and melanoma.
US Pat. No. 10,597,732

ALLOGENEIC AUTOPHAGOSOME-ENRICHED COMPOSITION FOR THE TREATMENT OF DISEASE

UbiVac, LLC, Portland, O...

1. A composition, comprising:an enriched population of autophagosomes derived from a non-small cell lung carcinoma cell line, the enriched population of autophagosomes including:
one or more toll-like receptor agonists;
one or more tumor antigens; and
one or more damage-associated molecular pattern molecules acting as a natural adjuvant;
wherein the non-small cell lung carcinoma cell line is selected based on the composition providing for a dose-dependent induction of BDCA3 in peripheral blood mononuclear cells upon interaction of the enriched population of autophagosomes with the peripheral blood mononuclear cells.
US Pat. No. 10,597,733

DETECTING GASTRIC NEOPLASM

Mayo Foundation for Medic...

1. A method comprising:a) extracting genomic DNA from a biological sample of a human individual suspected of having or having a neoplasm of the gastrointestinal system;
b) treating the extracted genomic DNA with bisulfite;
c) amplifying the bisulfite-treated genomic DNA using a pair of primers specific for each of ARHGEF4 and ELMO1; and
d) measuring the methylation level of the CpG site for each of ARHGEF4 and ELMO1 by methylation-specific PCR, quantitative methylation specific PCR, methylation-sensitive DNA restriction enzyme analysis, or bisulfite genomic sequencing PCR.
US Pat. No. 10,597,734

GENETIC MARKERS FOR DIAGNOSIS OF TUBERCULOSIS CAUSED BY MYCOBACTERIUM TUBERCULOSIS

EUROPEAN MOLECULAR BIOLOG...

1. A method of detecting Mycobacterium tuberculosis in a clinical sample, said method comprising the steps of:a) removal of contaminants from the clinical sample to generate a contaminant-free clinical sample;
b) extraction of genomic DNA from the contaminant-free clinical sample;
c) designing a set of specific oligonucleotide primers that amplify a nucleic acid consisting of SEQ ID NO: 1 for use in RT-PCR;
d) performing PCR with the oligonucleotide primers of step c) on the genomic DNA of step b) to produce a PCR product; and
e) analyzing the PCR product obtained in step d) by electrophoresis or specific probe nucleotide sequence complementary to SEQ ID NO: 1.
US Pat. No. 10,596,199

METHODS OF TREATING OR PREVENTING RHEUMATIC DISEASE

MESOBLAST, INC., New Yor...

1. A method for treating a rheumatic disease in a subject, the method comprising systemically administering to the subject a therapeutically effective amount of a population of cells enriched for STRO-1+ multipotential cells sufficient to reduce one or more symptoms of rheumatic disease, thereby treating said rheumatic disease in said subject.
US Pat. No. 10,597,479

AMPHIPHILIC BRANCHED POLYDIORGANOSILOXANE MACROMERS

Alcon Inc., Fribourg (CH...

1. A silicone hydrogel contact lens, comprising a crosslinked polymeric material which comprises units of an amphiphilic branched polydiorganosiloxane macromer, wherein the amphiphilic branched polydiorganosiloxane macromer comprises:(1) at least first polydiorganosiloxane polymer chain having two terminal methacryloyl groups; and
(2) at least one first hydrophilic chain;
(3) at least one second hydrophilic polymer chain; and
(4) at least one second polydiorganosiloxane polymer chain at least one end of which is covalently connected to the second hydrophilic polymer chain,
wherein the first and second polydiorganosiloxane chains are derived from an ?,?-dimethacryloyl-terminated polydiorganosiloxane vinylic crosslinker comprising one or more ATRP-containing siloxane units having one substituent having an ATRP initiator, wherein the first hydrophilic chain is anchored covalently onto one single ATRP-containing siloxane unit of the first or second polydiorganosiloxane chain at one of the two ends of the first hydrophilic polymer chain and has one first terminal group at the other one of the two ends of the first hydrophilic polymer chain,
wherein the second hydrophilic polymer chain is (a) anchored covalently onto one single ATRP-containing siloxane unit of the first polydiorganosiloxane chain at one of the two ends of the second hydrophilic polymer chain, (b) has one second terminal group at the other one of the two ends of the second hydrophilic polymer chain, and (c) is covalently connected to covalently connected to one of the two ends of the second polydiorganosiloxane chain,
wherein the first and second terminal groups independent of each other are (meth)acryloxy group, (meth)acryloxy-C2-C4 alkoxy group, (meth)acrylamido-C2-C4 alkoxy group, (meth)acryloxy-C2-C4 alkylamino group, (meth)acrylamido-C2-C4 alkylamino group, C1-C6 substituted or unsubstituted alkoxy group, C2-C6 substituted or unsubstituted alkanoyloxy group, or C1-C6 substituted or unsubstituted alkylamino group, wherein the first and second hydrophilic polymer chains are composed of monomeric units of at least one hydrophilic vinylic monomer selected from the group consisting of (meth)acrylamide, N,N-dimethyl (meth)acrylamide, dimethylaminoethyl (meth)acrylate, dimethylaminoethyl (meth)acrylamide, N-vinyl-2-pyrrolidone, N-vinyl-N-methyl isopropylamide, N-vinyl-N-methyl acetamide, N-vinyl formamide, N-vinyl acetamide, N-vinyl isopropylamide, N-vinyl-N-methyl acetamide, hydroxyethyl (meth)acrylate, hydroxyethyl (meth)acrylamide, hydroxypropyl (meth)acrylamide, glycerol methacrylate, polyethylene glycol (meth)acrylate, polyethylene glycol C1-C4-alkyl ether (meth)acrylate having a number average molecular weight of up to 1500, and mixtures thereof,
wherein the silicone hydrogel contact lens, when being fully hydrated, has an oxygen permeability (Dk) of at least about 70 barrers, a water content of from about 25% to about 70% by weight, an elastic modulus of from about 0.20 MPa to about 1.2 MPa.
US Pat. No. 10,596,200

USE OF LIFR OR FGFR3 AS A CELL SURFACE MARKER FOR ISOLATING HUMAN CARDIAC VENTRICULAR PROGENITOR CELLS

Procella Therapeutics AB,...

1. A method for isolating human cardiac ventricular progenitor cells, the method comprising:1) providing a culture of human embryonic stem (ES) cells or induced pluripotent stem cells (iPSCs);
2) at day 0, activating Wnt/?-catenin signaling in said culture from step 1;
3) at day 3-5, inhibiting Wnt/?-catenin signaling in said culture from step 2 to generate human cardiac progenitor cells (CPCs);
4) at day 5-7, contacting said human CPCs from step 3 with one or more agents reactive with Leukemia Inhibitory Factor Receptor (LIFR) and/or Fibroblast Growth Factor Receptor 3 (FGFR3);
5) separating LIFR+ cells and/or FGFR3+ cells from negative cells; and
6) isolating the LIFR+ cells and/or FGFR3+ cells as LIFR+ and/or FGFR3+ human cardiac ventricular progenitor cells.
US Pat. No. 10,597,736

COMPOSITIONS AND METHODS FOR DETECTING VIRUSES IN A SAMPLE

Washington University, S...

1. A method to detect one or more viruses in a sample, the method comprising:a) contacting a sample with a panel comprising probes capable of specifically hybridizing to greater than 10,000 viral nucleic acid sequences;
b) isolating the probes that specifically hybridize to viral nucleic acid sequences within the sample;
c) sequencing the viral nucleic acid sequences isolated; and
d) comparing the sequences from (c) with a database comprising reference viral nucleic acid sequences to determine the identity of the viral nucleic acid in the sample;
wherein the panel of probes targets complete viral genomes.
US Pat. No. 10,596,201

DELIPIDATED, DECELLULARIZED ADIPOSE TISSUE MATRIX

Musculoskeletal Transplan...

1. A delipidated, decellularized adipose tissue matrix derived from a first sample of adipose tissue which has been delipidated prior to decellularizing, wherein the delipidated, decellularized adipose tissue matrix contains a first proportion of lipids which is less than a second proportion of lipids contained in a processed adipose tissue derived from a second sample of adipose tissue which has been decellularized prior to delipidating.
US Pat. No. 10,597,481

HYDROGENATED BLOCK COPOLYMER

KURARAY CO., LTD., Kuras...

1. A hydrogenated block copolymer prepared by hydrogenating a block copolymer that comprises a polymer block (A) comprising a structural unit derived from an aromatic vinyl compound, a polymer block (B) comprising a structural unit derived from farnesene, and a polymer block (C) comprising a structural unit derived from a conjugated diene other than farnesene,wherein:
the block copolymer comprises at least two of the polymer blocks (A), at least one of the polymer block (B) and at least one of the polymer block (C), and wherein at least one of the polymer block (B) is at a terminal,
50 mol % or more of a total of carbon-carbon double bonds in the at least one polymer block (B) and in the at least one polymer block (C) are hydrogenated,
the hydrogenated block copolymer comprises a structure that comprises the polymer block (B), the polymer block (A), and the polymer block (C), in that order, and
an order-disorder transition temperature (ODT) of the hydrogenated block copolymer, as measured by dynamic viscoelastometry, is 290° C. or lower.
US Pat. No. 10,597,737

CHROMOPHORE-BASED METHODS AND KITS FOR DETECTING GENETIC VARIATIONS IN POLYNUCLEOTIDE ANALYTES

CALIFORNIA INSTITUTE OF T...

1. A method of detecting at least one genetic variation in a polynucleotide analyte in a sample, comprising:a) combining the sample comprising the polynucleotide analyte with a first primer and a second primer, wherein a fluorophore is attached to the first primer, a quencher is attached to the second primer, the first primer and the second primer are specific for the polynucleotide analyte and the fluorophore is different from the quencher;
b) measuring a first signal generated by the fluorophore and quencher;
c) performing at least one polymerization reaction with the first primer and the second primer using the polynucleotide analyte as a template;
d) measuring a second signal generated by the fluorophore and quencher;
e) comparing the first and second signals to determine a change between the first and second signals; and
f) determining the presence or absence of the at least one genetic variation based i) on the change in signal as determined in step e); and ii) by further comparing said change to the change in signal observed for an analyte without the at least one genetic variation.
US Pat. No. 10,596,202

COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING TISSUE INJURY AND DISEASE

MicroVascular Tissues, In...

1. A method for the treatment of nerve damage, comprising administering a therapeutic agent to a subject in need thereof, wherein the therapeutic agent comprises enriched, nonviable multipotent cells, wherein the nerve damage comprises peripheral neuropathy.
US Pat. No. 10,597,482

TWO-STAGE METHOD FOR PRODUCING A POLYURETHANE HOT-MELT ADHESIVE WITH A LOW CONTENT OF MONOMERIC DIISOCYANATE AND A HIGH INITIAL STRENGTH

SIKA TECHNOLOGY AG, Baar...

1. A two-stage method for producing a polyurethane hotmelt adhesive, which method comprisesA) reacting at least one polyol with at least one diisocyanate wherein the NCO/OH ratio is in a range of from above 1.5 to 2.2 to obtain a reaction mixture containing an isocyanate-functional polyurethane prepolymer and unconverted diisocyanate, wherein the unconverted diisocyanate content of the reaction mixture obtained in stage A) is from 1.5 to 5 wt %, based on the total weight of the reaction mixture, and
B) reacting the reaction mixture obtained in stage A), containing the isocyanate-functional polyurethane prepolymer and unconverted diisocyanate, with at least one polyester polyol wherein the NCO/OH ratio is above 3; wherein
at least one polyacrylate or polymethacrylate is admixed.
US Pat. No. 10,596,203

CUSTOMIZED REPAIR CONSTRUCTS AND METHOD OF PREPARATION

Brahm Holdings, LLC, Ger...

1. A method for preparing a customized tissue repair construct for a specific tissue repair site comprisingmeasuring the tissue repair site via a three-dimensional scanner or computed tomography (CT) scanner;
preparing a scaffold according to an additive manufacturing process selected from the group consisting of direct metal laser sintering (DMLS) process, an electron beam melting (EBM) process, selective laser sintering (SLS), stereolithography (SLA), and laminated object manufacturing; and
infiltrating the scaffold with a flowable/injectable human birth tissue product consisting of amniotic fluid and human amniotic membrane to form a tissue repair construct,
wherein the scaffold consists of one or more biomaterials selected from the group consisting of human placenta derived extracellular matrix (ECM), glycosaminoglycans, fibronectin, and laminin, and
wherein the scaffold is prepared according to a predetermined size based on the size of the tissue repair site thereby resulting in a customized tissue repair construct.
US Pat. No. 10,597,483

COMPACT ELASTOMER MOLDED PARTS ON THE BASIS OF POLYURETHANE

BASF SE, Ludwigshafen (D...

1. A process for the production of pore-free polyurethane elastomer moldings with a Shore D hardness of at least 60 in accordance with DIN 53505, the process comprising:mixing
(a) a polyesterdiol with OH number from 20 to 100 mg KOH/g and
(b) a chain extender composed of diol with molar mass below 300 g/mol, with
(c) isocyanate prepolymers obtainable via reaction of diisocyanate with polyesterols with functionality from 1.95 to 2.2 and with OH number from 20 to 200 mg KOH/g
to give a reaction mixture;
charging the mixture to a mold; and
hardening the mixture to form the polyurethane elastomer, wherein the ratio by weight of polyesterdiol (a) to chain extender (b) is in the range from 70:30 to 40:60.
US Pat. No. 10,597,739

PROBIOTIC BIFIDOBACTERIUM STRAIN

PrecisionBiotics Group Li...

1. A formulation for oral administration to a subject, the formulation comprising isolated strain Bifidobacterium longum deposited with NCIMB under accession number NCIMB 41676, wherein the Bifidobacterium longum strain is in the form of a powder.
US Pat. No. 10,596,204

USE OF PROPOLIS FOR COMBATING PATHOLOGICAL CONDITIONS ASSOCIATED WITH OBESITY

POLLENERGIE, Saint Hilai...

1. A method for treating type II diabetes associated with diet-induced obesity comprising administering to a subject in need thereof an effective amount of a composition comprising at least one poplar propolis extract that comprises 25%-35% polyphenols by weight of dry material,wherein the extract comprises in particular
at least 8% (±0.8%) pinocembrine,
at least 5% (±0.5%) chrysin,
at least 4% (±0.4%) galangin, and
at least 1.8% (±0.18%) CAPE,with the percentages being given by weight of dry material relative to the total polyphenols that are present in the extract; andwherein the daily dose of the composition comprises between 400 and 1000 mg of propolis extract by weight of dry material.
US Pat. No. 10,597,484

POLYISOCYANURATE PLASTICS HAVING HIGH THERMAL STABILITY

Covestro Deutschland AG, ...

1. A process for producing polyisocyanurate plastics, comprising the following steps:a) providing a polyisocyanate composition A) which contains oligomeric polyisocyanates and is low in monomeric diisocyanates, where the isocyanurate structure content in the polyisocyanate composition A) is at least 50 mol %, based on the sum total of the oligomeric structures from the group consisting of uretdione, isocyanurate, allophanate, biuret, iminooxadiazinedione and oxadiazinetrione structure that are present in the polyisocyanate composition A);
b) catalytically trimerizing the polyisocyanate composition A).
US Pat. No. 10,597,740

BIFIDOBACTERIUM LONGUM CBT BG7 STRAIN FOR PROMOTION OF GROWTH AND NUTRACEUTICAL COMPOSITION FOR PROMOTION OF GROWTH CONTAINING THE SAME

CELL BIOTECH CO., LTD., ...

1. A method for alleviating one or more conditions selected from the group consisting of growth retardation, development retardation, and low body weight in a subject selected from the group consisting of human neonates, infants, and growing children, the method comprising administering to the subject a nutraceutical composition, wherein the nutraceutical composition comprises:an effective amount of Bifidobacterium longum CBT BG7 strain deposited under accession number KCTC 12200BP; and
an excipient or a carrier,
wherein said bacteria strain is lyophilized.
US Pat. No. 10,596,205

TOPICAL MEDICAMENT FOR SKIN AND MUCOSAL INJURIES

REV PHARMA Corp., Miami,...

1. A method for treating lesions of dental, vaginal or anal surfaces, comprising:a) applying to internal lesions of mucosal dental, mucosal vaginal or mucosal anal surfaces of a patient in need of treatment for said lesions a dressing gauze or bandage without prior cleaning of said mucosal surfaces, wherein distributed on said dressing is an effective amount of a composition containing: about 15% to about 30% petroleum icily, about 5% to about 10% cod liver oil, about 15% to about 30% beeswax, about 5% to about 10% flax seed oil, about 5% to about 10% grape seed oil, and about 5% to about 10% chia oil, an added vitamin selected from the group consisting of vitamin A, D and E; and a pharmaceutically acceptable excipient and a preservative:
b) removing said dressing at least twice per day without damaging the patient's mucosal surfaces due to removal of the dressing.
US Pat. No. 10,597,485

PRODUCTION METHODS FOR GLASSY LIQUID-CRYSTALLINE EPOXY RESIN AND GLASSY LIQUID-CRYSTALLINE EPOXY RESIN COMPOSITION, STORAGE METHODS FOR LIQUID-CRYSTALLINE EPOXY RESIN AND LIQUID-CRYSTALLINE EPOXY RESIN COMPOSITION, GLASSY LIQUID-CRYSTALLINE EPOXY RESIN AN

HITACHI CHEMICAL COMPANY,...

1. A production method for a glassy liquid-crystalline epoxy resin, comprising a process of cooling a liquid-crystalline epoxy resin to cause transition into a glassy state.
US Pat. No. 10,597,741

HIGH-STRENGTH STEEL SHEET AND METHOD FOR MANUFACTURING THE SAME

JFE STEEL CORPORATION, T...

1. A method for manufacturing a high-strength steel sheet, the method comprising, when annealing by a continuous annealing method a steel sheet having a chemical composition comprising: C: 0.03% to 0.35%, by mass %, Si: 0.01% to 0.50%, by mass %, Mn: 3.6% to 8.0%, by mass %, Al: 0.01% to 1.0%, by mass %, P: 0.10% or less, by mass %, S: 0.010% or less, by mass %, and Fe and incidental impurities:performing a heating process in an annealing furnace at a heating rate of 7° C./s or more at a temperature in the range of 450° C. to A° C., where A: 500?A?600;
controlling the maximum end-point temperature of the steel sheet in the annealing furnace to be in the range of 600° C. to 700° C.;
controlling the traveling time of the steel sheet in a steel sheet temperature range of 600° C. to 700° C. to be in the range of 30 seconds to 10 minutes; and
controlling the dew point of the atmosphere in the steel sheet temperature range of 600° C. to 700° C. to be ?40° C. or lower.
US Pat. No. 10,596,206

PROBIOTIC COMPOSITIONS AND METHODS OF USE

Cornell University, Itha...

1. A probiotic composition comprising a therapeutically effective amount of two or more isolated lymphoid tissue-resident commensal bacteria selected from the group consisting of Alcaligenes faecalis, Achromobacter xylosoxidans, Ochrobactrum anthropi, Ochrobactrum intermedium, Bordetella holmesii, and Bordetella hinzii, wherein the composition does not contain bacteria belonging to gamma-proteobacteria, bacteriodetes phylum, and firmicutes phylum.
US Pat. No. 10,597,487

STRAPS PRODUCED FROM RENEWABLE RAW MATERIALS

Mosca GmbH, Waldbrunn (D...

1. An extruded strapping tape which is uniaxially stretched and which is weldable with itself and which is made of a renewable raw material that is a poly lactic acid (PLA),wherein the strapping tape has a width in a range of 4 millimeters to 32 millimeters,
wherein the strapping tape has a thickness in a range of 0.2 millimeters to 2 millimeters, and
wherein the poly lactic acid is made of at least of 90 wt. % L-lactic acid.
US Pat. No. 10,597,743

PROCESS FOR PRODUCING A HIGH-GRADE STEEL TUBE AND HIGH-GRADE STEEL TUBE

1. A method for manufacturing a stainless steel tube comprising the steps of:providing a tubular hollow of an austenitic stainless steel, wherein the stainless steel comprises:
carbon in an amount of not more than 0.02 wt.-%,
manganese in an amount of not more than 1.0 wt.-%,
phosphor in an amount of not more than 0.03 wt.-%,
sulfur in an amount of not more than 0.015 wt.-%,
silicon in an amount of not more than 0.8 wt.-%,
nickel in an amount from 17.5 wt.-% to 18.5 wt.-%,
chromium in an amount from 19.5 wt.-% to 20.5 wt.-%,
molybdenum in an amount from 6.0 wt.-% to 6.5 wt.-%,
nitrogen in an amount from 0.18 wt.-% to 0.25 wt.-%,
copper in an amount from 0.5 wt.-% to 1.0 wt.-%, and
a remainder of iron and unavoidable impurities;
cold forming the hollow into a tube;
coiling the tube;
annealing the coiled tube after the cold forming at a temperature in a range from 1,100° C. to 1,200° C.; and
recoiling the annealed coiled tube onto a reel without straightening the annealed coiled tube after the annealing.
US Pat. No. 10,601,075

METHOD FOR SYNTHESIZING HYDROCARBON ELECTROLYTES POLYMER AND POLYMERIZATION SOLVENT USED THEREIN

YOULCHON CHEMICAL CO., LT...

1. A mixture for synthesizing a sulfonated polyether sulfone consisting ofa monomer,
a polymerization catalyst and
a polymerization solvent,
wherein the monomer is a mixture of (i) 4,4?-dilpidroxydiphenyl or bisphenol A; (ii) bis(4-chlorophenyl) sulfone or bis(4-fluorophenyl)sulfone; and (iii) 3,3?-disulfonated-4,4?-chlorodiphenylsulfone or 3,3?-disulfonated-4,4?-fluorodiphenylsulfone,
wherein the polymerization solvent is a mixed solvent of a first solvent and a second solvent,
the first solvent being dimethyl acetamide, and
the second solvent being methanol,
wherein a mixing ratio of the first solvent and the second solvent is 15-30:10-20 by volume.
US Pat. No. 10,596,208

COMPOSITION FOR PREVENTING OR TREATING OBESITY OR LIPID-RELATED METABOLIC DISEASE

Cell Biotech Co., Ltd., ...

1. A method for treating a lipid-related metabolic disease, the method comprising a step of administering to a subject in need of treatment a therapeutically effective amount of a composition containing probiotics and a vitamin B complex,wherein the lipid-related metabolic disease is selected from the group consisting of hyperlipidemia, arteriosclerosis, hypertension, and cardiovascular diseases;
wherein the probiotics comprise Enterococcus faecium and Lactobacillus rhamnosus;
wherein the vitamin B complex comprises vitamin B1, vitamin B2, vitamin B6 and vitamin B7; and
wherein the probiotics promote the absorption of the vitamin B complex.
US Pat. No. 10,596,720

METHOD FOR REDUCING THE EMISSION OF VOLATILE ORGANIC COMPOUNDS MADE OF WOOD MATERIALS, AND WOOD MATERIALS

SWISS KRONO TEC AG, Luce...

1. A process for the production of wood-based materials made of lignocellulose, the wood-based materials being reduced in its emission of volatile organic compounds (VOCs) inclusive of terpenes, acids and aldehydes, comprising the following steps:a) provisioning of lignocellulose-containing comminution products;
b) bringing the lignocellulose-containing comminution products into contact with a combination of additives with a first component made of a porous carbon and a second component made of a hydrogensulfite salt; and
c) compression-molding of the lignocellulose-comminution products admixed with the combination of additives, with heat treatment, with adhesive to produce the wood-based materials.
US Pat. No. 10,597,488

PROCESS FOR PREPARING POLY(ESTER-CARBONATE)S AND POLY(ESTER-CARBONATE)S PREPARED THEREBY

SABIC GLOBAL TECHNOLOGIES...

1. A method of preparing a poly(ester-carbonate), themethod comprising
contacting an aqueous solution comprising a dicarboxylic acid with a first solution comprising phosgene and a first organic solvent in a tubular reactor to provide a first reaction mixture comprising the dicarboxylic acid, the corresponding diacid chloride, phosgene, or a combination comprising at least one of the foregoing;
combining a dihydroxy aromatic compound, the corresponding dialkali metal salt of the dihydroxy aromatic compound, or a combination comprising at least one of the foregoing, water, and a second organic solvent to provide a second reaction mixture;
introducing the first reaction mixture, the second reaction mixture, and a second solution comprising phosgene to a tank reactor, wherein the tank reactor has a first pH of 7 to 9; and
subsequently raising the pH to 9 to 11 to provide a third reaction mixture comprising the poly(ester-carbonate).
US Pat. No. 10,596,209

MICROBIAL COMPOSITIONS AND METHODS FOR TREATING TYPE 2 DIABETES, OBESITY, AND METABOLIC SYNDROME

Solarea Bio, Inc., Cambr...

1. A pharmaceutical composition comprising a mixture of a plurality of purified, viable microbes, wherein at least two microbes have at least 99 percent identity to any of Seq ID Nos. 1, 2, 3, 5, 9, 22, or 53 at the 16S rRNA or fungal ITS locus, and wherein the pharmaceutical composition is formulated in an oral dosage form selected from the group consisting of powder, tablet, capsule, caplet, granules, pellets, emulsion, and syrup.
US Pat. No. 10,596,722

CERAMIC FORMED BODY EXTRUSION METHOD, CERAMIC FORMED BODY, AND CERAMIC POROUS BODY

NGK Insulators, Ltd., Na...

1. A ceramic formed body extrusion method for forming a ceramic formed body having a wall-shaped or plate-shaped formed portion,by using an extrusion die provided with a slit for extrusion of a ceramic formed body having a wall-shaped or plate-shaped formed portion from a raw material for forming, the slit including a slit former stage unit located on an upstream side in an extrusion direction and a slit latter stage unit located on a downstream side in the extrusion direction, the slit latter stage unit having a width of from 3 to 27 times a width of the slit former stage unit, and
by extruding a raw material containing a first particle having an aspect ratio of from 2 to less than 300 such that the raw material passes though the slit former stage unit of the extrusion die and then passes through the slit latter stage unit.
US Pat. No. 10,597,490

PROCESS FOR PURIFICATION OF CRUDE POLYETHER POLYOLS

BASF SE, Ludwigshafen am...

1. A process for purifying a crude polyether polyol prepared by anionic polymerization of an alkylene oxide in the presence of a basic catalyst, the process comprisingneutralizing the catalyst with a mineral acid to form a salt,
adding an adsorption agent and/or a filter aid,
removing the salt and the adsorption agent and/or the filter aid by filtration to form a filter cake, and
subsequently pressing the filter cake to recuperate the polyether polyol from the filter cake.
US Pat. No. 10,597,746

HIGH-STRENGTH STEEL HAVING A HIGH MINIMUM YIELD LIMIT AND METHOD FOR PRODUCING A STEEL OF THIS TYPE

THYSSENKRUPP STEEL EUROPE...

7. A method of manufacturing a flat steel product comprising:producing a steel melt that includes
iron,
0.23%-0.25% by weight carbon,
0.15%-0.35% by weight silicon,
0.85%-1.00% by weight manganese,
0.07%-0.10% by weight aluminum,
0.65%-0.75% by weight chromium,
0.02%-0.03% by weight niobium,
0.55%-0.65% by weight molybdenum,
0.035%-0.05% by weight vanadium,
1.10%-1.30% by weight nickel,
0.0020%-0.0035% by weight boron,
0.0007%-0.0030% by weight calcium, and
at least one of
?0.012% by weight phosphorus,
?0.003% by weight sulfur,
?0.10% by weight copper,
?0.006% by weight nitrogen,
?0.008% by weight titanium,
?0.03% by weight tin,
?2.00 ppm hydrogen,
?0.01% by weight arsenic, or
?0.01% by weight cobalt;
reducing a content of hydrogen by a vacuum treatment of the steel melt;
casting the steel melt to form a slab;
heating the slab to a temperature in a range of 1100° C. to 1250° C.;
descaling the slab;
hot rolling the slab to give a flat steel product, wherein an initial rolling temperature in the hot rolling is in a range of 1050° C. to 1250° C. and a final rolling temperature is at least 880° C.,
wherein a carbon equivalent CET is greater than or equal to 0.43% by weight and less than or equal to 0.49% by weight, where the carbon equivalent CET is calculated according to the following formula:
CET=[C]+([Mn]+[Mo])/10+([Cr]+[Cu])/20+[Ni]/40,where [C], [Mn], [Cr], [Mo], [Cu], and [Ni] are proportions by mass of the respective elements in the high-strength steel in percent by weight.
US Pat. No. 10,596,211

MEDICATION DISPENSING SYSTEM

1. A method of treating human in need of a sedative or a narcotic consisting essentially of administering to the human in need thereof via a patch, pill, or hydrogel, an isolated cannabidiol or an isolated cannabigerol, and an oil selected from the group consisting of soybean oil, linseed oil, palm oil, castor oil, coconut oil, angelica oil, anise oil, arnica oil, valerian oil, bergamot oil, savory oil, cassia oil, chenopodium oil, chrysanthemum oil, citronella oil, lemon oil, citrus oil, costus oil, curcuma oil, carlina oil, elemi oil, tarragon oil, eucalyptus oil, fennel oil, pine needle oil, pine oil, galbanum oil, geranium oil, guaiac wood oil, hazelwort oil, iris oil, hypericum oil, calamus oil, camomile oil, fir needle oil, garlic oil, coriander oil, caraway oil, lavender oil, lemon grass oil, lovage oil, bay oil, mace oil, marjoram oil, mandarin oil, melissa oil, mint oil, clary oil, nutmeg oil, spikenard oil, clove oil, neroli oil, olibanum oil, opopranax oil, opoponax oil, orange oil, oregano oil, orthosiphon oil, patchouli oil, parsley oil, petit grain oil, peppermint oil, tansy oil, rosewood oil, rose oil, rosemary oil, rue oil, saffron oil, sage oil, sandalwood oil, sassafras oil, celery oil, mustard oil, immortelle oil, fir oil, teatree oil, terpentine oil, thyme oil, juniper oil, frankincense oil, hyssop oil, cedar wood oil, cinnamon oil, cypress oil, fish oil and combinations thereof.
US Pat. No. 10,596,212

MANGIFERA INDICA AS A SIRTUIN 1 ACTIVATING AGENT

VITAL SOLUTIONS SWISS AG,...

1. A method of preventing, treating or ameliorating Sirtuin 1 related conditions or disorders, which method comprises:administering a Magnifera indica fruit preparation to an individual in need thereof, wherein administering the Magnifera indica fruit preparation improves and/or maintains a healthy body composition, improves and/or maintains healthy glucose or insulin management, improves and/or maintains a healthy lipid metabolism, prevents and/or treats being overweight, maintains well aging, improves and/or maintains a healthy energy homeostasis, protects cells, repairs DNA and/or maintains physical power and/or muscle mass during aging in the individual, wherein the Magnifera indica fruit preparation is obtained from Magnifera indica fruit having a green to yellow color and dried directly after harvesting.
US Pat. No. 10,597,493

POLYIMIDE PRECURSOR COMPOSITION AND METHOD OF PREPARING POLYIMIDE MOLDED ARTICLE

FUJI XEROX CO., LTD., To...

1. A polyimide precursor composition comprising a solvent and a polyimide precursor including a group having a triple bond at a terminal thereof, which is dissolved in the solvent,wherein the solvent comprises water and a compound selected from the group consisting of morpholines and amino alcohols, and
wherein a content of the compound selected from the group consisting of morpholines and amino alcohols is from 80 mol % to 120 mol % with respect to a carboxy group (—COOH) of the polyimide precursor in the polyimide precursor composition.
US Pat. No. 10,596,214

METHODS AND COMPOSITIONS FOR TREATING STRIAE DISTENSAE

Mary Kay Inc., Addison, ...

1. A method of treating a stretch mark in a person's skin, the method comprising topically applying to the stretch mark an effective amount of a topical composition comprising a combination of vegetable amino acids from navy bean, Myrciaria dubia fruit extract, Peucedanum graveolens extract, and tetrahexyldecyl ascorbate, wherein the combination decreases redness, increases smoothness, increases elasticity, increases firmness, and/or decreases thickness of a stretch mark.
US Pat. No. 10,597,494

THERMOPLASTIC (CO)POLYIMIDES AND SYNTHESIS METHODS

Rhodia Operations, Paris...

1. A salt composition, comprising:at least one ammonium carboxylate salt obtained from:
(a) at least one aromatic compound comprising 2 anhydride functional groups and/or its carboxylic acid and/or ester derivatives selected from the group consisting of: pyromellitic anhydride, 3,3?,4,4?-biphenyltetracarboxylic dianhydride, pyromellitic acid, 3,3?,4,4?-biphenyltetracarboxylic acid and their mixtures; and
(b) one or more aliphatic diamines, the amine functional groups of which are not covalently bonded to a carbon atom of an aromatic ring, in which said one or more aliphatic diamines are of formula (I) NH2—R—NH2 with R being a saturated aliphatic divalent hydrocarbon radical, the two amine functional groups of which are separated by 4 to 6 carbon atoms and 1 or 2 hydrogen atoms of the divalent radical of which are replaced by 1 or 2 methyl and/or ethyl groups; and wherein the one or more aliphatic diamines optionally further comprises at least one diamine of formula (II) NH2—R?—NH2 with R? being a saturated or unsaturated and aliphatic, cycloaliphatic or arylaliphatic divalent hydrocarbon radical, which optionally comprises heteroatoms; and
at least one chain-limiting compound chosen from monoamines, monoacids or diacids in the ?,? positions such that they can form an anhydride functional group by a dehydration reaction, wherein the at least one chain-limiting compound is added to a preformed ammonium carboxylate salt.
US Pat. No. 10,599,031

GLASS SUBSTRATE FOR MASK BLANK, MASK BLANK AND PHOTOMASK

AGC Inc., Chiyoda-ku (JP...

7. A mask blank comprising:a glass substrate; and
a film formed on a surface of the glass substrate, wherein:
the glass substrate comprises a first surface and a second surface, which face each other and each of which is approximately square having a vertical length (P) and a horizontal length (P) being equal to the vertical length (P);
in the first surface, a first square having a center coinciding with a center of the first surface and sides which are parallel with respective sides of the first surface and have a length P1 of 104 mm, a second square having a center coinciding with the center of the first surface and sides which are parallel with the respective sides of the first surface and have a length P2 of 132 mm, and a third square having a center coinciding with the center of the first surface and sides which are parallel with the respective sides of the first surface and have a length P3 of 142 mm, are assumed;
a region inside the first square, the region including the first square, is referred to as a central region,
a region enclosed by the second square and the first square, the region including the second square but not including the first square, is referred to as a peripheral region,
a region enclosed by the third square and the second square, the region including the third square but not including the second square, is referred to as an edge region,
a region inside the second square, the region including the second square, is referred to as a non-edge region, and
a region inside the third square, the region including the third square, is referred to as an effective region;
in the effective region of the first surface, 100 or more vertical lines are drawn in the vertical direction at same interval d and 100 or more horizontal lines are drawn in the horizontal direction at same interval d, and a profile is recognized by measuring relative heights at respective measurement positions in a cross section taken along each of the vertical lines and the horizontal lines;
the profile of the first surface is judged as a convex profile if an average value of heights at measurement positions on all of the vertical lines and the horizontal lines in the central region is higher than an average value of heights at measurement positions on all of the vertical lines and the horizontal lines in the peripheral region, whereas the profile of the first surface is judged as a concave profile if the average value of heights at the measurement positions on all of the vertical lines and the horizontal lines in the central region is lower than the average value of heights at the measurement positions on all of the vertical lines and the horizontal lines in the peripheral region;
among the vertical lines, a vertical line that crosses, in the following order, the edge region which is referred to as a first section of the edge region, the peripheral region which is referred to as a first section of the peripheral region, the central region, the peripheral region which is referred to as a second section of the peripheral region, and the edge region which is referred to as a second section of the edge region, is referred to as a particular vertical line;
among the horizontal lines, a horizontal line that crosses, in the following order, the edge region which is referred to as a third section of the edge region, the peripheral region which is referred to as a third section of the peripheral region, the central region, the peripheral region which is referred to as a fourth section of the peripheral region, and the edge region which is referred to as a fourth section of the edge region, is referred to as a particular horizontal line;
a peak-to-valley (PV) value in the effective region is 70 nm or less;
(i) in a case where the profile of the first surface is the convex profile, when a profile curve is drawn by a curve fitting based on each measurement point in the non-edge region in a profile in a cross section taken along each of the particular vertical line and the particular horizontal line, an extrapolation curve having a first portion ?1 in the first section or third section of the edge region and a second portion ?2 in the second section or fourth section of the edge region is drawn by extrapolating the profile curve to the ends of the effective region, and a first reference curve R1 and a second reference curve R2 are drawn by adding 3 nm to heights of the first portion ?1 and the second portion ?2, respectively,
a mode which a first straight line obtained by straight-line-approximating measurement points of the profile in the first section or third section of the edge region is located under the first reference curve R1 and a second straight line obtained by straight-line-approximating measurement points of the profile in the second section or fourth section of the edge region is located under the second reference curve R2 holds in 75% or more of the cross sections taken along all of the particular vertical lines and the particular horizontal lines; and
(ii) in a case where the profile of the first surface is the concave profile, when a profile curve is drawn by a curve fitting based on each measurement point in the non-edge region in a profile in a cross section taken along each of the particular vertical lines and the particular horizontal lines, an extrapolation curve having a first portion ?1 in the first section or third section of the edge region and a second portion ?2 in the second section or fourth section of the edge region is drawn by extrapolating the profile curve to the ends of the effective region, and a first reference curve R1 and a second reference curve R2 are drawn by subtracting 3 nm from heights of the first portion ?1 and the second portion ?2, respectively,
a mode which a first straight line obtained by straight-line-approximating measurement points of the profile in the first section or third section of the edge region is located over the first reference curve R1 and a second straight line obtained by straight-line-approximating measurement points of the profile in the second section or fourth section of the edge region is located over the second reference curve R2 holds in 75% or more of the cross sections taken along all of the particular vertical lines and the particular horizontal lines.
US Pat. No. 10,596,215

CHINESE HERBAL ORAL PASTE FOR CONDITIONING DAMPNESS-HEAT CONSTITUTION AND PROCESSING METHOD THEREOF

1. A Chinese herbal oral paste for conditioning dampness-heat constitution, comprising the following components in parts by weight: 5-15 parts of baical skullcap root, 5-15 parts of unprocessed rehmannia root, 4-16 parts of plantain seed, 12-28 parts of purslane herb, 3-17 parts of angelica, 1-5 parts of cardamon fruit, 5-19 parts of virgate wormwood herb, 9-21 parts of rice beans, 5-15 parts of weeping forsythia capsule, 5-16 parts of thunberg fritillary bulb, 10-30 parts of Chinese waxgourd peel, 3-9 parts of mint, 2-9 parts of dried tangerine peel, 7-19 parts of prepared atractylodes rhizome, 8-22 parts of waxgourd seed, 2-9 parts of common anemarrhena rhizome, 4-16 parts of amur cork-tree, 8-23 parts of golden buckwheat rhizome, 7-18 parts of fuling, 6-18 parts of Chinese yam, 5-15 parts of bitter apricot seed, 11-27 parts of coix seed, 5-16 parts of bamboo leaf, 8-20 parts of Chinese wolfberry root-bark, 2-9 parts of ural licorice root tip, 9-22 parts of common selfheal fruit-spike, 6-18 parts of white mulberry root-bark, 5-17 parts of ash bark, 7-25 parts of tortoise-plastron gelatin, 15-35 parts of turtle shell gelatin, and 20-30 parts of xylitol.
US Pat. No. 10,597,495

AGED POLYMERIC SILSESQUIOXANES

Dow Silicones Corporation...

1. An aged polymeric silsesquioxane that is a product made by a process comprising heating step (a) or (b), wherein heating step (a) is comprised of substeps (a)(1) and (a)(2):(a)(1) heating a silsesquioxane resin prepolymer at a temperature of from 150 degrees Celsius (° C.) to 300° C. for a time of at least 10 seconds to give a cured polymeric silsesquioxane, and then (a)(2) heating the cured polymeric silsesquioxane at a temperature of from 500° to 700° C. for at least 30 minutes to give the aged polymeric silsesquioxane, wherein the silsesquioxane resin prepolymer is of formula (I): (HSiO(3-h)/2(OH)h)x(RArSiO(3-h)/2(OH)h)y(RAlkSiO(3-h)/2(OH)h)z wherein each RAr independently is phenyl or naphthyl, each RAlk independently is (C1-C3)alkyl, subscript x is a mole fraction from 0.20 to 0.94, subscript y is a mole fraction from 0.06 to 0.80, subscript z is a mole fraction from 0 to 0.70, the sum x+y+z=1, and each h independently is 0, 1 or 2, wherein in the silsesquioxane resin prepolymer of formula (I) the mole percent, w1, of units having SiOH groups is from 6 to 38 mole percent; or
(b) heating a cured polymeric silsesquioxane at a temperature of from 500° to 700° C. for at least 30 minutes to give the aged polymeric silsesquioxane;
wherein in the heating step (a) or (b) the cured polymeric silsesquioxane independently is of formula (I): (HSiO(3-h)/2(OH)h)x(RArSiO(3-h)/2(OH)h)y(RAlkSiO(3-h)/2(OH)h)z (I), wherein each RAr independently is phenyl or naphthyl, each RAlk independently is (C1-C3)alkyl, subscript x is a mole fraction from 0.20 to 0.94, subscript y is a mole fraction from 0.06 to 0.80, subscript z is a mole fraction from 0 to 0.70, the sum x+y+z=1, and each h independently is 0, 1 or 2, wherein in the cured polymeric silsesquioxane of formula (I) the mole percent, w2, of units having SiOH groups is from 1 to 20 mole percent; and wherein w1>w2; and
wherein the silsesquioxane resin prepolymer of formula (I) is characterized by a first mass, mass1, and the aged polymeric silsesquioxane is characterized by a second mass, mass2, wherein mass2=from 0.85 mass1 to 1.02 mass1.
US Pat. No. 10,596,216

USE OF A WITHANIA EXTRACT FOR THE TREATMENT OF AMYLOID-RELATED DISEASES

Ethnodyne and Centre Nati...

1. A composition containing a Withania somnifera extract for a use to treat or prevent amyloid-related diseases in a mammal, wherein the Withania somnifera extract has been fermented by its incubation with a filamentous fungus in a suitable environment.
US Pat. No. 10,596,728

POLYMER POWDER FOR POWDER BED FUSION METHODS

Evonik Operations GmbH, ...

1. A method for producing a polymer powder having a surface energy of less than 35 mN/m, said method comprising:coating a polymer powder with a hydrophobic substance, thereby obtaining the polymer powder having a surface energy of less than 35 mN/m.
US Pat. No. 10,596,217

COMPOSITIONS CONTAINING A WITHANIA SOMNIFERA EXTRACT INCUBATED WITH A FILAMENTOUS FUNGUS OF THE BEAUVARIA GENUS

Ethnodyne, Paris (FR) Ce...

1. Composition containing a Withania somnifera extract fermented by incubation of the Withania somnifera extract with a filamentous fungus from the genus Beauveria in a suitable environment for a use of the composition to treat or prevent ?-synucleinopathies in a mammal.
US Pat. No. 10,596,218

COIX SEED OIL CONTAINING 16 GLYCERIDES, AND PHARMACEUTICAL PREPARATION AND USE THEREOF

ZHEJIANG KANGLAITE GROUP ...

1. A Coix seed oil, comprising 5 diglyceride and 11 triglyceride ingredients in the following mass percentages: 1,3-diolein 0.40-0.58%, 1-linolein-3-olein 0.91-1.31%, 1,2-diolein 0.24-0.35%, 1-olein-2-linolein 0.66-0.95%, 1,2-dilinolein 0.33-0.47%, trilinolein 4.87-6.99%, 1-olein-2,3-dilinolein 13.00-18.69%, 1-palmitin-2,3-dilinolein 5.25-7.54%, 1,3-diolein-2-linolein 13.23-19.02%, 1-palmitin-2-linolein-3-olein 10.26-14.75%, 1,3-dipalmitin-2-linolein 2.28-3.28%, triolein 14.44-20.76%, 1-palmitin-2,3-diolein 8.06-11.58%, 1-olein-2-linolein-3-stearin 1.37-1.97%, 1,3-dipalmitin-2-olein 1.52-2.19% and 1,2-diolein-3-stearin 1.29-1.86%.
US Pat. No. 10,597,498

METHOD OF PRODUCING CRYSTALLINE POLYCARBONATE POWDERS

SABIC GLOBAL TECHNOLOGIES...

1. A method of preparing a partially crystalline polycarbonate powder, the method comprising:dissolving an amorphous polycarbonate in a halogenated alkane solvent to form a solution;
combining the solution with a crystallizing non-solvent that is miscible with the halogenated alkane solvent, under high shear mixing conditions effective to form a partially crystalline polycarbonate precipitate having
a D90 particle size of less than 150 micrometers;
an average particle diameter of less than or equal to 100 micrometers; and
at least 20% crystallinity;
wherein the crystallizing non-solvent is acetone, methyl ethyl ketone, or a combination comprising at least one of the foregoing.
US Pat. No. 10,599,035

METHOD OF IMPROVING LIGHT STABILITY OF FLEXOGRAPHIC PRINTING PLATES FEATURING FLAT TOP DOTS

MacDermid Graphics Soluti...

1. A photocurable flexographic printing blank comprising:a) a support layer;
b) one or more photocurable layers disposed on the support layer, wherein the one or more photocurable layers comprise:
i) a binder;
ii) one or more monomers;
iii) an alpha-aminoketone photoinitiator, wherein the alpha-aminoketone photoinitiator comprises 2-methyl-1-(4-methylthiophenyl)-2-morpholinpropan-1-one; and
iv) an additive selected from the group consisting of phosphites, phosphines, thioether amine compounds, and combinations of one or more of the foregoing;
c) a laser ablatable masking layer disposed on the one or more photocurable layers, the laser ablatable masking layer comprising a radiation opaque material; and
d) optionally, a removable coversheet.
US Pat. No. 10,599,036

CHEMICALLY AMPLIFIED POSITIVE-TYPE PHOTOSENSITIVE RESIN COMPOSITION

TOKYO OHKA KOGYO CO., LTD...

8. The chemically amplified positive photosensitive resin composition according to claim 1, wherein the protected resin is acrylic resin (B1-c), which is produced by protecting an unprotected acrylic resin with an acid-dissociative dissolution-controlling group or a polymer or copolymer of a monomer having a carboxyl group protected with an acid-dissociative dissolution-controlling group.
US Pat. No. 10,597,500

METHOD FOR PRODUCING COMPOSITE MATERIAL AND COMPOSITE MATERIAL

MITSUBISHI GAS CHEMICAL C...

1. A method for producing a composite material, comprising:combining a solid resin precursor and a reinforcing fiber; and
polycondensing the resin precursor with pressing under vacuum of a degree of vacuum of 0.005 MPa or less.
US Pat. No. 10,597,501

FIBERS WITH FILLER

GPCP IP Holdings LLC, At...

1. A paper web comprising:a cellulosic substrate having a surface; and
a fiber or a film impregnated within the cellulosic substrate, having a particle size with an average diameter of about 1 micrometer to about 80 micrometers, and comprising:
a binder and a filler, the binder being a polyvinyl alcohol (PVOH) with a degree of hydrolysis of greater than 95%, the filler being deinking waste solids comprising ash and cellulose fines, the PVOH being present in an amount in a range between about 20 weight % (wt. %) to about 99 wt. % based on the total weight of the article, and the cellulose fines comprising an average diameter of about 1 to about 200 micrometers.
US Pat. No. 10,599,038

RINSING LIQUID, PATTERN FORMING METHOD, AND ELECTRONIC DEVICE MANUFACTURING METHOD

FUJIFILM Corporation, To...

1. A pattern forming method comprising the successive steps of:a resist film forming step of forming a resist film using an actinic ray-sensitive or radiation-sensitive composition,
an exposure step of exposing the resist film,
a step of developing the exposed resist film using a developer containing an organic solvent, and
a step of rinsing the developed resist film using a rinsing liquid comprising hydrocarbon-based solvent having a branched alkyl group, wherein the hydrocarbon-based solvent having a branched alkyl group comprises a mixture of compounds having a same number of carbon atoms and different structures, and at least one of the compounds is isodecane or isododecane,
wherein the number of carbon atoms in each of the compounds is 10 or more.
US Pat. No. 10,597,502

ION EXCHANGE MEMBRANES

Fujifilm Manufacturing Eu...

1. A composite ion exchange membrane obtainable by a process comprising reacting an ionically-charged membrane with a composition comprising:(a) a monofunctional ethylenically unsaturated monomer having an ionic charge opposite to the charge of the ionically-charged membrane; and
(b) a crosslinking agent comprising two or more ethylenically unsaturated groups;
wherein the molar ratio of (b):(a) is lower than 0.04 or is zero,
wherein the ionically-charged membrane has been obtained by a process comprising the polymerisation of a composition comprising a crosslinking agent and a monofunctional ethylenically unsaturated monomer having an ionic charge.
US Pat. No. 10,596,223

JNK INHIBITOR MOLECULES FOR TREATMENT OF VARIOUS DISEASES

Xigen Inflammation Ltd., ...

1. A method of treating interstitial cystitis in a subject in need of treatment thereof, the method comprising administering to the subject a fusion peptide comprising a c-Jun amino terminal kinase (JNK) inhibitor peptide and a transporter peptide, wherein the fusion peptide comprises the amino acid sequence of rKKRrQRRrRPkRPaTLNLf (SEQ ID NO: 172), wherein an amino acid residue given in capital letters indicates an L-amino acid and an amino acid residue given in small letters indicates a D amino acid residue.
US Pat. No. 10,597,503

PREPREG AND FIBER REINFORCED COMPOSITE MATERIAL

TORAY INDUSTRIES, INC., ...

1. A prepreg comprising at least the following components [A] to [F], wherein the ratio Ne/Nd, with Ne being the number of structures of component [F] present in a range of outside 110% of the particle diameter of component [E] and Nd being the number of structures of component [F] present in a range of outside 110% of the particle diameter of component [D], is 0.25 or more, wherein in a range of outside 110% of the particle diameter of component [E] means that component [F] is distributed in an area protruding outside from the circumference of a particle of component [E] by a length of 10% of the diameter of the particle of component [E] where the diameter of the particle of component [E] is taken as 100%, wherein in a range of outside 110% of the particle diameter of component [D] means that component [F] is distributed in an area protruding outside from the circumference of a particle of component [D] by a length of 10% of the diameter of the particle component [D] where the diameter of the particle of component [D] is taken as 100%, and wherein a structure of component [F] has a size within a range of 40 to 500 nm in terms of number-average particle size; andwherein:[A]: carbon fibers;
[B]: thermosetting resin;
[C]: hardener;
[D]: particles containing a thermoplastic resin having a primary particle number-average particle size of 5 to 50 ?m as a primary component;
[E]: conductive particles different from component [D] and having a primary particle number-average particle size in the range of the following formula (1)
[(A×0.1)+4]?Psize?[(A×0.1)+14]  formula (1);
Psize: a primary particle number-average particle size (?m) of component [E] conductive particles,
A: areal weight of component [A] in the prepreg, wherein A is 135 to 270 g/m2; and
[F]: filler consisting of a carbon material;wherein at least one of the following formula (2) to formula (4) is satisfied where the zeta-potential of component [D] is expressed by ?d and the zeta-potential of component [F] is expressed by ?f,?10 mV ?10 mV ?d×?f>0  formula (4);wherein zeta-potential of each of component [D] and component [F] is measured at a voltage of 60 V, at room temperature (23° C.±2° C.) using ethanol as a dispersion medium by using an electrophoretic light scattering photometer, with a sample being prepared so as to have a concentration of 0.1 wt % relative to the dispersion medium and then used as a measurement solution and the measurement being carried out five times and the average value thereof defined as zeta-potential ? (mV).
US Pat. No. 10,596,224

METHOD OF TREATING A WOUND, COMPRISING THE STEP OF ADMINISTERING A COMPOSITION INCLUDING A SUBSTANCE P

Biosolutions Co., Ltd, S...

1. A method of treating a wound, comprising administering a composition comprising a thickener, an antioxidant, a surfactant, and substance P consisting of an amino acid sequence of SEQ ID NO: 1 to a subject in need thereof,wherein the thickener is hydroxyethyl cellulose;
wherein the antioxidant is sodium thiosulfate; and
wherein the surfactant is polysorbate 80.
US Pat. No. 10,597,504

LOW TEMPERATURE PROCESS FOR INTEGRATING A POLYMERIC FOAM WITH A POLYMERIC BODY

INSTITUTO DE CAPACITACION...

1. A low temperature process for integrating a polymeric foam with at least one polymeric body which comprises the steps of:a. providing at least one polymeric body;
b. providing a polymeric material to be foamed at a temperature between the glass transition temperature and the crystal melting temperature for a material that crystallizes, or at a temperature below the glass transition temperature for a material that does not crystallize, wherein the polymeric material to be foamed is different from the polymeric body but compatible with the polymeric body, and wherein the polymeric material to be foamed undergoes the following process:
(i) contacting the polymeric material to be foamed with a gas at a pressure greater than atmospheric pressure until the polymeric material to be foamed incorporates at least 0.1% gas by weight,
(ii) exposing the polymeric material to be foamed from step (i) to atmospheric pressure, and
(iii) exposing the polymeric material to be foamed from step (ii) to a pressure greater than atmospheric pressure and a temperature greater than the crystal melting temperature of the polymeric material to be foamed of step b) for a material that crystallizes, or the glass transition temperature of the polymeric material to be foamed of step b) for a material that does not crystallize, and lower than the temperature that avoids polymeric body deformation to obtain a polymeric material impregnated with gas, wherein the temperature that avoids polymeric body deformation ranges between 110° C. and 130° C., and
c. integrating the polymeric material impregnated with gas obtained from step b)(iii) with the at least one polymeric body at a pressure lower than the pressure used in step b)(iii), such that the impregnated gas is liberated permitting foaming of the polymeric material,wherein,the polymeric material is selected from the group consisting of ethylene-vinyl acetate (EVA), ethylene-butyl acrylate (EBA), medium density polyethylene (MDPE), low density polyethylene(LDPE), linear low density polyethylene (LLDPE), copolymers of polypropylene (PP), ionomers, and mixtures thereof;
the polymeric body is selected from the group consisting of high density polyethylene (HDPE), polypropylene (PP), polycarbonate (PC), polyamide (PA), and polyethylene terephthalate (PET);
step b)(iii) and step c) are performed through extrusion, injection molding, or combinations thereof; and
the time range in step b)(ii) is between 20 min and 70 minutes.
US Pat. No. 10,597,760

HIGH-STRENGTH STEEL MATERIAL FOR OIL WELL AND OIL WELL PIPES

NIPPON STEEL CORPORATION,...

1. A high-strength steel material for oil well having a chemical composition consisting, by mass percent, ofC: 0.85 to 1.4%,
Si: 0.05 to 1.00%,
Mn: 12 to 25%,
Al: 0.003 to 0.06%,
P: 0.03% or less,
S: 0.03% or less,
N: less than 0.1%,
V: 0 to 0.5%,
Nb: 0 to 0.5%,
Ta: 0 to 0.5%,
Ti: 0 to 0.5%,
Zr: 0 to 0.5%,
Ca: 0% or more and less than 0.005%,
Mg: 0% or more and less than 0.005%,
B: 0 to 0.015%, and
one or more elements selected from
Cr: 0.1% or more and less than 5.0%,
Mo: 0.1% or more and less than 3.0%,
Cu: 0.1% or more and less than 1.0%, and
Ni: 0.1% or more and less than 1.0%, and
the balance: Fe and impurities,
wherein Nieq defined by the following Formula (i) is 32.7 or higher,
a metal micro-structure is a structure consisting of
a total volume fraction of ferrite and ?? martensite: less than 0.10%,
a volume fraction of ? martensite: 10% or less,
the balance: an FCC structure, and
a yield strength is 862 MPa or higher;
the high-strength steel material for oil well, has
a) sulfide stress-corrosion cracking resistance (SSC resistance) defined as having no rupture after being immersed in Solution A for at 24° C. for 336 hours,
b) stress corrosion cracking resistance (SCC resistance) defined as having no rupture after being immersed in Solution A for at 60° C. for 336 hours, and
c) a corrosion rate of 1.5 g/m2h or lower after being immersed in Solution A for at 24° C. for 336 hours,wherein solution A is a 5% NaCl+0.5% CH3COOH aqueous solution, 1-bar H2S saturated, as specified in NACE TM0177-2005;Nieq=Ni+30C+0.5Mn  (i)
where, each symbol Ni, C and Mn in the formula represents a content of the element contained in the high-strength steel material by mass percent, and is made zero in a case where the element is not contained.
US Pat. No. 10,596,225

TISSUE OCCLUDING AGENT COMPRISING AN IEIKIEIKIEIKI PEPTIDE

3-D Matrix, Ltd., Tokyo ...

1. A method for occluding a site of tissue damage in a mammal, the method comprising steps of;(a) removing excess body fluid from a site of tissue damage from which body fluid is leaking (“a body fluid leakage site”);
(b) applying to the body fluid leakage site a composition comprising a solution of a peptide whose amino acid sequence consists of SEQ ID NO:8.
US Pat. No. 10,596,226

ALBUMIN-PROAEROLYSIN PRODRUGS

The Johns Hopkins Univers...

1. A recombinant protein comprising SEQ ID NO:48.
US Pat. No. 10,597,506

PROCESS FOR EXTRACTION OF BIOPLASTIC AND PRODUCTION OF MONOMERS FROM THE BIOPLASTIC

BIOEXTRAX AB, Malmo (SE)...

1. A process for extraction of bioplastic from bioplastic-producing microbial cells, comprising the steps of:A. providing a composition of bioplastic producing microbial cells having cell walls, the cells containing bioplastic as granules;
B. providing active bacterial cells selected from the species Bacillus pumilus having the ability to lyse the cell walls of the bioplastic-producing microbial cells;
C. lysing the bioplastic producing microbial cells by contacting the bioplastic-producing microbial cells of step A and the bacterial cells of step B and allowing reaction, where said contacting active B. pumilus cells does not consume bioplastic from the bioplastic-producing microbial cells; and
D. applying a procedure of recovery of the bioplastic from the lysing of the microbial cells of step C, which procedure of recovery can be repeated after washing the bioplastic, wherein recovery is of an amount of at least 85% of the bioplastic of step A, a purity of at least 88% by weight, and a molecular weight distribution consistent with the bioplastic of step A;
wherein said lysing and recovering steps are organic solvent free and chemical free.
US Pat. No. 10,596,227

POLYPEPTIDE TARGETING TO MITOCHONDRIA

United Kingdom Research a...

1. A fusion protein that binds to a point mutation in mutant mitochondrial DNA (mtDNA), the fusion protein comprising:(a) a zinc finger protein (ZFP) DNA-binding polypeptide comprising 3 zinc fingers, wherein the ZFP binds specifically to a target sequence in the mutant mtDNA, wherein the target sequence comprises the point mutation;
(b) a functional domain which modifies the mutant mtDNA;
(c) a mitochondrial targeting sequence (MTS); and
(d) a nuclear export sequence (NES), wherein the fusion protein is localized in a mitochondria of a cell.
US Pat. No. 10,597,507

POLYMER-MODIFIED ASPHALT WITH WAX ADDITIVE

GreenMantra Recycling Tec...

1. A method for forming a wax and employing said wax to modify asphalt, the method comprising:(a) selecting a solid polymeric material;
(b) heating said solid polymeric material in an extruder to produce a molten polymeric material;
(c) filtering said molten polymeric material;
(d) placing said molten polymeric material through a chemical depolymerization process in a reactor to produce a depolymerized wax material;
(e) adding said depolymerized wax material to a pre-wax mixture to produce a polymer-modified asphalt.
US Pat. No. 10,596,228

METHODS FOR INCREASING LEVELS OF INTERFERON ACTIVITY WITH AN INTERFERON LAMBDA 3 POLYPEPTIDE

RUTGERS, THE STATE UNIVER...

1. A method for upregulating MHC class I antigen expression, said method comprising administering to an individual a composition comprising an effective amount of an interferon lambda 3 (IFN-?3) polypeptide.
US Pat. No. 10,597,764

SUBSTRATE FOR HOT-DIP GALVANIZING OR HOT-DIP GALVANNEALING, PRODUCTION METHOD THEREFOR, AND HOT-DIP GALVANIZED STEEL SHEET OR HOT-DIP GALVANNEALED STEEL SHEET

Kobe Steel, Ltd., Kobe-s...

1. A substrate for hot-dip galvanizing or hot-dip galvannealing, which is a substrate obtained by subjecting a steel sheet comprising in percent by mass:C: from 0.06% to 0.3%,
Si: from 1.00% to 1.6%,
Mn: from 1% to 3%, and
Al: from more than 0% to 0.1%,
and satisfying a mass ratio of Si/Mn of 1.0 or less, to reduction annealing,
wherein
when a mapping intensity of Fe, which is observed in a measurement field of view of 33.6 ?m×41.4 ?m on a surface of the substrate by performing mapping of Fe using an electron probe microanalyser, of 0 to 240 is divided into 16 parts at an interval of 15, an area occupied by a mapping intensity of 195 or more relative to the whole measurement field of view is an area rate of 70% or more.
US Pat. No. 10,596,229

METHOD OF TREATING DIABETES MELLITUS BY ADMINISTRATION, AT SPECIFICALLY DEFINED INTERVALS, OF A DERIVATIVE OF A NATURALLY OCCURRING INSULIN OR INSULIN ANALOGUE, THE DERIVATIVE HAVING A PROLONGED PROFILE OF ACTION

1. A method of treating type 1 or type 2 diabetes comprising:administering to a patient in need thereof a pharmaceutically effective dosage of a derivative of a naturally occurring insulin or of an insulin analogue, wherein said insulin derivative exhibits a prolonged profile of action and wherein said dosages are administered at intervals, wherein at least one of said intervals has a length of
i. at least 1.3 times the mean of said intervals, or
ii. no more than 0.85 times the mean of said intervals,
wherein the mean of said intervals is at least 12 hours, and less than 36 hours,
wherein said dosage is not adjusted between administrations, and
wherein said derivative of said naturally occurring insulin or said insulin analogue is LysB29(N?hexadecandioyl-?-Glu) des(B30) human insulin.
US Pat. No. 10,597,509

SUPPORTED CATALYST WITH IMPROVED FLOWABILITY

Univation Technologies, L...

1. A polymerization process comprising contacting at least one monomer with:a polyolefin catalyst comprising a catalyst support, wherein the catalyst support has an average particle size of about 2 microns to about 200 microns, and a catalyst supported on the catalyst support; and
nanoparticles adhered to the catalyst support, wherein the nanoparticles have an average particle size of about 2 to about 200 nanometers.
US Pat. No. 10,597,765

STEEL, CARBURIZED STEEL COMPONENT, AND METHOD FOR MANUFACTURING CARBURIZED STEEL COMPONENT

NIPPON STEEL CORPORATION,...

1. A steel, whereina chemical composition comprises, by mass %,
C: 0.07% to 0.13%,
Si: 0.0001% to 0.50%,
Mn: 0.0001% to 0.80%,
S: 0.0050% to 0.0800%,
Cr: more than 1.30% to 5.00% or less,
B: 0.0005% to 0.0100%,
Ti: 0.020% or more to less than 0.100%,
Al: 0.010% to 0.100%,
Bi: more than 0.0001% to 0.0100% or less,
N: 0.0080% or less,
P: 0.050% or less,
O: 0.0030% or less,
Nb: 0% to 0.100%,
V: 0% to 0.20%,
Mo: 0% to 0.500%,
Ni: 0% to 1.000%,
Cu: 0% to 0.500%,
Ca: 0% to 0.0030%,
Mg: 0% to 0.0030%,
Te: 0% to 0.0030%,
Zr: 0% to 0.0050%,
a rare earth metal: 0% to 0.0050%,
Sb: 0% to 0.0500%, and
a remainder including Fe and impurities,
wherein a hardenability index Ceq obtained by substituting the amount of each element in the chemical composition indicated by mass % in Expression 1 ranges from greater than 7.5 to smaller than 44.0,
wherein a metallographic structure includes ferrite ranging from 85 to 100 area %,
wherein an average distance between sulfides, which are observed in a cross section parallel to a rolling direction of the steel and have an equivalent circle diameter ranging from 1 ?m or greater to smaller than 2 ?m, is shorter than 30.0 ?m, and
wherein a presence density of the sulfides, which are observed in the cross section parallel to the rolling direction of the steel and have an equivalent circle diameter ranging from 1 ?m or greater to smaller than 2 ?m, is 300 pieces/mm2 or more,
Ceq=(0.7×Si+1)×(5.1×Mn+1)×(2.16×Cr+1)×(3×Mo+1)×(0.3633×Ni+1)  (Expression 1).
US Pat. No. 10,596,230

METHODS OF INCREASING NUTRIENT ABSORPTION IN THE INTESTINE USING THERAPEUTIC AGENTS COMPRISING GLP-2 AND ELASTIN-LIKE PEPTIDES

DUKE UNIVERSITY, Durham,...

1. A method of increasing nutrient absorption in the intestine in a patient in need thereof comprising administering to the subject a therapeutic composition comprising a GLP-2 peptide in a fusion with an elastin-like peptide (ELP) comprising at least 90 repeating units of VPGXG (SEQ ID NO: 3) and a pharmaceutically acceptable carrier or excipient, and wherein the fusion protein exhibits an increased half-life in serum compared to an unfused GLP-2 peptide.
US Pat. No. 10,597,510

FLAKY GLASS GRANULES AND RESIN COMPOSITION USING THE SAME

NIPPON SHEET GLASS COMPAN...

1. Flaky glass granules comprising:glass flakes having an average thickness of 0.1 to 2.0 ?m and an average particle diameter of 10 to 2000 ?m; and
a binder that binds the glass flakes together into the flaky glass granules,
wherein the flaky glass granules comprise 1.0 to 5.0% by mass of the binder in terms of solid content, and
the binder contains an adhesive component and 0.1 to 9% by mass of the binder of a coupling agent.
US Pat. No. 10,596,231

INSULIN CONTAINING PHARMACEUTICAL COMPOSITIONS

1. A pharmaceutical composition comprising A14E, B16H, B25H, B29K((N?-Eicosanedioyl-?Glu-[2-(2-{2-[2-(2-aminoethoxy)ethoxy] acetylamino}ethoxy)ethoxy]-acetyl)), desB30 human insulin (Compound 1), from about 1 to about 2% (weight/weight) glycerol; from about 45 to about 75 mM phenol; from about 0 to about 19 mM m-cresol; from about 1.5 to about 2.5 moles of zinc ions per six moles of Compound 1; less than about 25 mM sodium chloride; and having a pH value in the range of from 7.2 to 8.0.
US Pat. No. 10,596,488

LITHIUM ION EXTRACTION METHODS

University of South Flori...

1. A method of extracting lithium ions from an organic solvent, the method comprising:providing a liquid ion source containing lithium ions and an organic solvent selected from the group consisting of acetone, acetonitrile, butanone, 1,2-dichloroethane, diethylene glycol, diglyme (diethylene glycol dimethyl ether), 1,2-dimethoxyethane (DME), dimethyl formamide (DMF), dimethyl sulfoxide (DMSO), dioxane, ethyl acetate, ethylene glycol, methyl t-butyl ether (MTBE), N-methyl-2-pyrrolidinone (NMP), tetrahydrofuran (THF), toluene, and mixtures thereof, wherein the liquid ion source is substantially free of water;
contacting said liquid ion source with an ion capture substrate, wherein the ion capture substrate comprises a plurality of polyethylenediimine moieties, each of the plurality of polyethylenediimine moieties having the formula —CH2CH2NHCH2NHCH2CH2—, or a plurality of polymethylethylenediimine moieties, each of the plurality of polymethylethylenediimine moieties having the formula —N(CH3)CH2CH2N(CH3)—, wherein each of said moieties are covalently attached to an immobilization substrate, and adsorbing the lithium ions onto said moieties; and
removing the ion capture substrate with the lithium ions adsorbed thereon from the organic solvent.
US Pat. No. 10,596,233

USE OF PERTUSSIS TOXIN AS A THERAPEUTIC AGENT

Dignity Health, San Fran...

1. A method of reducing migration of microglia into neurologically damaged tissue in a human subject's spinal cord, the method comprising the steps of:providing a composition comprising pertussis toxin (PTx) comprising subunits A and B; and
reducing the migration of microglia into the neurologically damaged tissue of the human subject's spinal cord via administering a therapeutically effective dosage of the composition to the human subject, wherein the human subject has multiple sclerosis.
US Pat. No. 10,597,513

COTTONSEED OIL BASED ADDITIVE COMPOSITIONS FOR PLASTICS MOLDING AND EXTRUSION

1. A method of molding or extruding plastic parts comprising the steps of:a) providing a collection of additives, at least one of which is a solid;
b) providing a quantity of pure cottonseed oil;
c) creating a plurality of single additive dispersions each in a cottonseed oil carrier;
d) mixing selected ones of the single additive dispersions to create a blend;
e) milling the blend while the cottonseed oil is in a liquid phase; and
f) adding the blend to thermoplastic resin in the course of molding or extrusion.
US Pat. No. 10,596,234

COMPOSITIONS AND METHODS TO INHIBIT VIRAL REPLICATION

University of Southern Ca...

1. An isolated polynucleotide encoding a RIG-I-QQ mutant, complementary polynucleotides and equivalents of each thereof, wherein the encoded RIG-I-QQ mutant is a polypeptide that comprises the amino acid substitution(s) N495Q and/or N549Q according to SEQ ID NO:4.
US Pat. No. 10,596,235

PHARMACEUTICAL PREPARATION

1. A method for the treatment of pancreatic insufficiency comprising the steps of:providing a pharmaceutical composition consisting of water and a bacterial lipase, and which has been stored for at least one week, and
administering the pharmaceutical composition to a patient suspected of pancreatic insufficiency.
US Pat. No. 10,597,516

METHOD OF MANUFACTURING COMPOSITE PRODUCTS COMPRISING A CARBOHYDRATE-BASED BINDER

1. A method for the preparation of a composite product comprising fibers and/or particles and/or sheet material bonded with a binder comprising (i) providing a binder composition comprising a carbohydrate component and a cross-linker comprising at least 10% and less than 50% by dry weight of the binder composition and, optionally, at least one reaction product of the carbohydrate component and the cross-linker, wherein the cross-linker is selected from the group consisting of ammonium salts of inorganic acid, carboxylic acids, ammonium salts thereof, ester and anhydride derivatives thereof, and combinations thereof, (ii) adding to the binder composition an additional amount of 0.5-10 wt. % based on the total dry weight of the binder composition of an amine compound comprising at least two amine functional groups selected from primary and secondary amines, and the amine compound is selected from (a) aliphatic monoamines, the aliphatic group being a straight or branched saturated or unsaturated alkyl or hetero-alkyl chain comprising 2-24 C-atoms or cycloalkyl or cycloheteroalkyl or an aromatic carbon ring structure, each optionally substituted by a hydroxy, carboxyl, halo, cyanate, sulfonyl or thiol functional groups, (b) compounds of the general formula H2N-Q-NH2, wherein Q is a straight or branched alkyl or heteroalkyl functional group comprising 2-24 C-atoms, cycloalkyl, or cylcoheteroalkyl, an aromatic carbon ring structure, optionally substituted by a hydroxy, carboxyl, halo, cyanate, sulfonyl and/or thiol functional group, (c) whey or soy protein, optionally modified or denatured, (d) polyprimary amines comprising a molecular weight of 5000 or less and 10 wt. % or more of primary amine groups based on the weight of the polyamine, (d) polyamino acids selected from lysine, ornithine, diaminobutyric acid and diaminopropionic acid, or (f) polyetheramines, polyethyleneimines, polyethyleneimine comprising copolymers and block copolymers, polyvinylamines, (co)polymers of aminoethyl methacrylate, (iii) applying the composition obtained under (ii) onto the fibers, particles and/or sheet material, and (iv) subjecting the product obtained under (iii) to heat and optionally pressure to effect drying and/or curing.
US Pat. No. 10,596,237

IDENTIFICATION OF PNEUMOCYSTIS ANTIGENS AND USES THEREOF

University of New Orleans...

1. A method of eliciting an immune response in a subject, comprising administering to the subject a GSC-1 protein comprising an amino acid sequence at least 90% identical to residues 22-606 of SEQ ID NO: 111.
US Pat. No. 10,596,238

METHODS AND COMPOSITIONS RELATED TO IMMUNOGENIC FIBRILS

The University of Chicago...

1. A peptide fibril comprising peptides coupled to a plurality of antigens, wherein the peptide fibril comprises a plurality of self-assembling peptides, wherein the self-assembling peptide comprises the amino acid sequence set forth in SEQ ID NO:1 or a variant thereof having amino acid substitutions at position 3, 5, 6 and/or 7 of SEQ ID NO:1, and wherein the antigen is covalently coupled to a terminus of the self-assembling peptide.
US Pat. No. 10,597,774

METHOD FOR PRODUCING A COATED SUBSTRATE

SAINT-GOBAIN GLASS FRANCE...

1. A process for obtaining a substrate provided, on at least one portion of at least one side, with a heat-treated coating, the process comprising:heat treating a coating provided on at least one portion of at least one side of said substrate with a pulsed or continuous laser radiation focused on said coating as a laser line provided by a plurality of lasers positioned to form the laser line having a cumulative laser length, wherein, in the heat treating, said substrate is substantially horizontal and travels on a conveyor facing the laser line,
wherein the heat treating substantially homogeneously treats the substrate while tolerating a variation in distance to the laser focal spot due to vibrations of the substrate while the speed of travel of the substrate is at least 3 meters per minute,
wherein, in the heat treating, the laser line has a combination of
a wavelength within a range of 400 to 1500 nm,
a beam parameter product (BPP) of at most 3 mm·mrad,
measured at a place where the laser line is focused on said coating, a linear power density divided by the square root of a duty cycle within a range from 200 W/cm to 1000 W/cm,
a length within a range of 20 cm to 100 cm,
a mean width within a range of 40 to 100 micrometers,
wherein a width of the laser line remains essentially constant throughout said heat treating such that a difference between a largest width and a smallest width of the laser line is at most 10% of the mean width when the displacement distance from the coating to the focal plane of the laser varies between ±1 mm, and
wherein the temperature reached by said coating at each point during said heat treating does not vary by more than 10% in relative terms compared to the targeted temperature when the displacement distance from the coating to the focal plane of the laser varies between ±1 mm.
US Pat. No. 10,596,239

PEPTIDE MIXTURE

Targovax ASA, Oslo (NO)

1. A method of stimulating the immune system in a human or animal subject with cancer, wherein the cancer is associated with RAS protein amino acid substitutions, the method comprising administering to the subject a peptide mixture suitable for eliciting an immune response in a human or animal subject with cancer, wherein the peptide mixture comprises a first, second, third, fourth, fifth and sixth peptide, each corresponding to a fragment of the RAS protein,wherein the first, second, third, fourth, fifth and sixth peptides are:
a peptide comprising the amino acid sequence of SEQ ID NO: 27,
a peptide comprising the amino acid sequence of SEQ ID NO: 28,
a peptide comprising the amino acid sequence of SEQ ID NO: 29,
a peptide comprising the amino acid sequence of SEQ ID NO: 30,
a peptide comprising the amino acid sequence of SEQ ID NO: 31, and
a peptide comprising the amino acid sequence of SEQ ID NO: 32, and
wherein each of the peptides comprises no more than 30 amino acids, in order to elicit an immune response in the subject.
US Pat. No. 10,597,519

SEVERELY HYDROTREATED NAPHTHENIC DISTILLATE CONTAINING RUBBER COMPOSITIONS

ContiTech USA, Inc., Fai...

1. A composition comprising:a) at least one synthetic rubber material;
b) a severely hydrotreated naphthenic distillate incorporated in amount of from 4% to 30% by weight of the composition; and,
c) a sulfur curative;
wherein after curing, the composition provides acceptable cold flexibility at a temperature lower than ?60 deg C.;
wherein ethylenepropylene-diene copolymer rubber is one of the at least one synthetic rubber material;
wherein all synthetic rubber material comprised in the at least one synthetic rubber material is incorporated in an amount from 22% by weight to 28% by weight based upon total composition weight and,
wherein the severely hydrotreated naphthenic distillate has a viscosity from 100 to about 121 SUS @ 37.8 deg C.
US Pat. No. 10,596,240

PEPTIDES AND COMBINATION OF PEPTIDES AS TARGETS OR ACTIVE INGREDIENTS FOR USE IN IMMUNOTHERAPY AGAINST AML AND OTHER CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. A method of eliciting an immune response in a patient who has cancer, comprising administering to the patient a population of activated T cells that kill the cancer cells which present a peptide consisting of the amino acid sequence SEQ ID NO: 12, wherein said cancer is acute myelogenous leukemia/acute myeloid leukemia (AML), wherein the activated T cells are cytotoxic T cells produced by in vitro contacting T cells with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell.
US Pat. No. 10,597,520

POLYOLEFIN BLENDS INCLUDING COMPATIBILIZER

Dow Global Technologies L...

1. A composition, comprising:(A) from 10 wt % to 90 wt % of an ethylene component including at least one ethylene based polymer having an ethylene content of at least 50.0 wt %, based on the total weight of the ethylene based polymer, a melt index from 0.1 g/10 min to 100.0 g/10 min (ASTM D-1238 at 190° C., 2.16 kg), and a density from 0.935 g/cm3 to 0.965 g/cm3;
(B) from 10 wt % to 90 wt % of a propylene component including at least one propylene based polymer having a propylene content of at least 50.0 wt %, based on the total weight of the propylene based polymer, and a melt flow rate from 0.5 g/10 min to 200.0 g/10 min (ASTM D-1238 at 230° C., 2.16 kg);
(C) from 1 wt % to 20 wt % of a composite component including a specified block composite, derived from at least ethylene and an alpha-olefin that is one of a C3-10 alpha-olefin, wherein:
the specified block composite includes an ethylene based polymer having an ethylene content from 69 mol % and to 90 mol %, an alpha-olefin based polymer that is derived from at least the alpha-olefin, and a block copolymer comprising an ethylene block and an alpha-olefin block, the ethylene block of the block copolymer having the same composition as the ethylene based polymer in the block composite, and the alpha-olefin block of the block copolymer having the same composition as the alpha-olefin based polymer of the block composite,
at least the specified block composite is present in the composite component and the alpha-olefin based polymer has an alpha-olefin content of from 61 mol % to 90 mol %; and
the specified block composite has a modified block composite index that is greater than 0 and less than 1.0.
US Pat. No. 10,595,728

SYSTEMS AND METHODS FOR PREDICTING TISSUE VIABILITY DEFICITS FROM PHYSIOLOGICAL, ANATOMICAL, AND PATIENT CHARACTERISTICS

HeartFlow, Inc., Redwood...

1. A computer-implemented method for estimating tissue viability of a patient's tissue, the method comprising:receiving tissue viability data for a plurality of individuals;
receiving data of one or more physiological or anatomical parameters, for each of the plurality of individuals;
training, by using a training set comprising the tissue viability data and the data of one or more physiological or anatomical parameters, a machine learning algorithm, wherein the machine learning algorithm maps the one or more physiological or anatomical parameters to tissue viability;
receiving image data derived from one or more images of a patient's anatomy;
generating one or more patient-specific models, each being a model of a vessel or tissue of the patient, using the image data;
calculating patient-specific values of the one or more physiological or anatomical parameters based on the one or more patient-specific models;
computing a tissue viability value by inputting the patient-specific values of the one or more physiological or anatomical parameters into the trained machine learning algorithm, wherein the trained machine learning algorithm includes feature weights defining an extent to which the one or more physiological or anatomical parameters are predictive of tissue viability; and
outputting, to an electronic storage medium or a display, the computed tissue viability value or a treatment plan generated based on the computed tissue viability value.
US Pat. No. 10,596,241

PEPTIDES AND COMBINATION OF PEPTIDES AS TARGETS OR ACTIVE INGREDIENTS FOR USE IN IMMUNOTHERAPY AGAINST AML AND OTHER CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. A method of eliciting an immune response in a patient who has cancer, comprising administering to the patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence SEQ ID NO: 52,wherein the activated T cells are cytotoxic T cells produced by in vitro contacting T cells with an antigen presenting cell that expresses the peptide in a complex with an WIC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell,
wherein said cancer is selected from the group consisting of acute myelogenous leukemia/acute myeloid leukemia (AML) and melanoma.
US Pat. No. 10,597,521

CURABLE COMPOSITION COMPRISING AN ETHYLENE POLYMER, A MONOPEROXYCARBONATE AND A T-ALKYL HYDROPEROXIDE

Arkema France, Colombes ...

1. A curable composition comprising:a) at least one ethylene polymer,
b) from more than 0 to less than 2 parts by weight of at least one monoperoxycarbonate for 100 parts by weight of constituent (a),
c) from 0.4 to less than 4 parts by weight of at least one t-alkyl hydroperoxide for 100 parts by weight of constituent (b).
US Pat. No. 10,596,242

TRANSFECTED T-CELLS AND T-CELL RECEPTORS FOR USE IN IMMUNOTHERAPY AGAINST CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. A method of treating a patient who has cancer that presents on the cell surface a peptide consisting of the amino acid sequence of KIQEILTQV (SEQ ID NO: 1) in complex with HLA-A*02, comprising administering to the patient a population of transformed CD8+ T cells expressing at least one vector encoding a T cell receptor (TCR),wherein the TCR comprises SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 15,
wherein the TCR is capable of binding to a peptide consisting of the amino acid sequence of KIQEILTQV (SEQ ID NO: 1) in a complex with HLA-A*02, and
wherein the cancer is selected from non-small cell lung cancer, small cell lung cancer, renal cell cancer, glioblastoma, gastric cancer, colorectal cancer, hepatocellular cancer, pancreatic cancer, chronic lymphocytic leukemia, acute myeloid leukemia, non-Hodgkin's lymphoma, melanoma, ovarian cancer, uterine cancer, and esophageal cancer.
US Pat. No. 10,597,522

POLYPROPYLENE COMPOSITIONS

SABIC GLOBAL TECHNOLOGIES...

1. A composition comprising(a) polypropylene having a melt mass flow rate as measured in accordance with ISO 1133 using a 2.16 kg weight and at a temperature of 230° C. in the range from 10 to 40 g/10 min and
(b) a polymer comprising polyoxymethylene,
wherein
the polypropylene (a) has a melt temperature TmPP and a crystallization temperature TcPP,
the polymer (b) has a melt temperature TmP and a crystallization temperature TcP,
wherein the TcP is 5-40° C. higher than TcPP,
wherein the Tm and Tc are determined using Differential Scanning calorimetry according to ASTM D 3418-08 using a scan rate of 10° C./min on a sample of 10 mg and using the second heating cycle,
wherein the composition comprises polyoxymethylene (POM) but not polyamide and the amount of POM in the composition is at least 0.3 wt % and at most 1 wt % based on the total weight of components a) and b) in the composition, and
wherein the clarity of the composition as measured according to ASTM D1746 is at least 30%.
US Pat. No. 10,596,243

PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST BREAST CANCER AND OTHER CANCERS

Immatics Biotechnologies ...

1. A method of treating cancer in a HLA-A*02+ patient having a cancer overexpressing a MAGED1 polypeptide comprising the amino acid sequence of SEQ ID NO: 24 and presenting at its surface a peptide consisting of SEQ ID NO: 24 in complex with an MHC class I molecule, said method comprising administering to said patient an effective amount of activated antigen-specific CD8+ cytotoxic T cells to selectively eliminate cancer cells,wherein said activated antigen-specific CD8+ cytotoxic T cells are produced by contacting CD8+ cytotoxic T cells with an antigen presenting cell presenting at its surface a peptide consisting of SEQ ID NO: 24 in complex with an MHC class I molecule in vitro,
wherein the cancer is selected from breast cancer, kidney cancer, brain cancer, liver cancer, non-Hodgkin lymphoma, acute myeloid leukemia, melanoma, esophageal cancer, uterine cancer, gallbladder cancer, bile duct cancer, and head and neck cancer.
US Pat. No. 10,597,523

ANTI-AGGLOMERANTS FOR POLYISOBUTYLENE PRODUCTION

BASF South East Asia Pte....

1. Aqueous slurry prepared by a process comprising:A) contacting an organic medium comprising
i) polyisobutylene and
ii) an organic diluent
with an aqueous medium comprising at least one lower critical solution temperature compound having a cloud point of 0 to 100° C., and
B) removing at least partially the organic diluent to obtain the aqueous slurry comprising the polyisobutylene particles,
wherein said at least one lower critical solution temperature compound is selected from the group consisting of poly(N-isopropylacrylamide), poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide, poly(N-isopropylacrylamide)-alt-2-hydroxyethylmethacrylate, poly(N-vinylcaprolactam), poly(N,N-diethylacrylamide), poly[2-(dimethylamino)ethyl methacrylate], poly(2- oxazoline)glypolyisobutylenes, poly(3-ethyl-N-vinyl-2-pyrrolidone), hydroxylbutyl chitosan, polyoxyethylene (20) sorbitan monostearate, polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan monooleate, hydroxypropyl cellulose, hydroxyethyl methylcellulose, hydroxypropyl methylcellulose, a poly(ethylene glycol) methacrylate comprising 2 to 6 ethylene glycol units, a polyethyleneglycol-co-polypropylene glycol, a compound of formula (I):
HO—[—CH2—CH2—O]x—[—CH(CH3)—CH2—O]y—[—CH2—CH2—O]z—H  (I)
wherein y=3 to 10 and x and z=1 to 8, whereby y+x+z is from 5 to 18, an ethoxylated iso-C13H27-alcohol, a polyethylene glycol comprising 4 to 50 ethyleneglycol units, a polypropylene glycol comprising 4 to 30 propyleneglycol units, a polyethylene glycol monomethyl ether comprising 4 to 50 ethyleneglycol units, a polyethylene glycol dimethyl ether comprising 4 to 50 ethyleneglycol units, a polyethylene glycol monoethyl ether comprising 4 to 50 ethyleneglycol units, a polyethylene glycol diethyl ether comprising 4 to 50 ethyleneglycol units, a polypropylene glycol monomethyl ether comprising 4 to 50 propyleneglycol units, a polypropylene glycol dimethyl ether comprising 4 to 50 propyleneglycol units, a polypropylene glycol monoethyl ether comprising 4 to 50 propyleneglycol units, and a polypropylene glycol diethyl ether comprising 4 to 50 propyleneglycol units.
US Pat. No. 10,596,244

PHARMACEUTICAL PREPARATION COMPRISING A COMBINATION OF STREPTOCOCCUS STRAINS AND LACTOBACILLUS STRAINS

WINCLOVE HOLDING B.V., A...

1. A method for the treatment of a multi-resistant Staphylococcus aureus (MRSA) induced infection or condition, wherein the MRSA induced infection or condition is present in/on at least one selected from a nasal region and a pharyngeal region, the method comprising:administering, to a human or animal that is an MRSA carrier, a combination of
a) one or more viable ?-Streptococcus strains chosen from the group consisting of Streptococcus sanguis II strains having the accession numbers NCIMB 40104, and NCIMB 40106, and Streptococcus mitis strains having the accession number NCIMB 40874, and
b) Lactobacillus rhamnosus strain LB21 having the accession number NCIMB 40564;
wherein the combination further includes at least one pharmaceutically acceptable medium.
US Pat. No. 10,596,245

STAPHYLOCOCCUS AUREUS MATERIALS AND METHODS

THE REGENTS OF THE UNIVER...

1. A method of treating S. aureus infection in a subject comprising administering to the subject an antibody product specific for:(i) an S. aureus alpha toxin epitope GFNGNVTGDDTGKIGGLIGAN (SEQ ID NO: 1),
(ii) an S. aureus alpha toxin epitope consisting essentially of GNVTGDDTGKIGGLIG (SEQ ID NO: 14) or
(iii) an immunogenic equivalent of the S. aureus alpha toxin epitope of (ii), wherein the immunogenic equivalent is a peptide consisting essentially of an amino acid sequence at least 90% identical to SEQ ID NO: 14.
US Pat. No. 10,597,525

RESIN COMPOSITION AND FILM THEREOF

KANEKA CORPORATION, Osak...

1. A resin composition comprising:a resin (A), and
a multilayer structure polymer (B),
wherein the multilayer structure polymer (B) has a crosslinked polymer layer and a hard polymer layer,
the resin (A) is not chemically bonded with the crosslinked polymer layer,
the resin composition has a sea-island structure comprising a dispersion of particles of the multilayer structure polymer (B) in the resin (A),
the hard polymer layer has at least two different hard polymer layers including a hard polymer layer (C) opposite in sign of a photoelastic constant to that of the resin (A) and a hard polymer layer (D),
no polyfunctional monomer is used for the hard polymer layer (C) and for the hard polymer layer (D), and
the resin (A) is an acrylic resin containing methyl methacrylate in an amount of 30 to 100 wt %.
US Pat. No. 10,596,246

ADJUVANTED COMBINATIONS OF MENINGOCOCCAL FACTOR H BINDING PROTEINS

GLAXOSMITHKLINE BIOLOGICA...

1. An immunogenic composition comprising an immunologically effective amount of a first factor H binding protein (fHbp) antigen and an immunologically effective amount of a second fHbp antigen, present as two separate polypeptides, and an immunologically effective amount of an aluminium phosphate adjuvant, wherein:the first fHbp antigen comprises an amino acid sequence wherein at least 90% of its amino acids are the same as both of SEQ ID NO: 26 and SEQ ID NO: 23, but wherein the percentage of amino acids that are the same as SEQ ID NO: 26 is higher than the percentage of amino acids that are the same as SEQ ID NO: 23, when aligned using the same algorithm and parameters; and
the second fHbp antigen comprises an amino acid sequence wherein at least 94% of its amino acids are the same as SEQ ID NO: 25.
US Pat. No. 10,596,247

METHODS AND COMPOSITIONS FOR ATTENUATED CHLAMYDIA AS VACCINE AND VECTOR

Board of Regents, The Uni...

1. An isolated Chlamydia trachomatis cell comprising:a) a substitution at Q117 in open reading frame CT849, wherein said amino acid numbering is based on the amino acid sequence of SEQ ID NO:1; and
b) a G216* mutation in open reading frame CT389, wherein said amino acid numbering is based on the amino acid sequence of SEQ ID NO:2,
wherein said Chlamydia trachomatis cell has a phenotype due to said substitution of (a) and said mutation of (b) of attenuated pathogenicity.
US Pat. No. 10,595,479

INDUCED MUTAGENESIS

Purdue Research Foundatio...

1. A method for creating a desired genetic variant from a plant, the method comprising:a. subjecting isolated pollen to a chemical mutagen and a reagent to impair DNA repair to produce a first generation seed;
b. planting the first generation seed in (n) plots to produce first generation plants;
c. recovering mutagenized pollen from the first generation plants;
d. pollinating a female parent of said first generation plant with the recovered mutagenized pollen to produce a next generation seed;
e. subjecting pollen from the next generation seed to mutagenesis to pollinate the first generation plant, resulting in a new next generation seed;
f. planting the new next generation seed to produce a new next generation plant; and
g. subjecting pollen from the new next generation plant to mutagenesis to pollinate the new next generation plant.
US Pat. No. 10,596,248

IMMUNOMODULATING COMPOSITION FOR TREATMENT

Jingang Medicine (Austral...


US Pat. No. 10,597,528

POLYMER COMPOSITION FOR THE MANUFACTURE OF INJECTION MOULDED ARTICLES

NOVAMONT S.P.A., Novara ...

1. A polymer composition for the production of injection moulded articles comprising, with respect to the sum of components i.-v.:i) 20-60% by weight of at least one polyester i. comprising:
a) a dicarboxylic component comprising with respect to the total dicarboxylic component:
a1) 0-20% in moles of units deriving from at least one aromatic dicarboxylic acid,
a2) 80-100% in moles of units deriving from at least one saturated aliphatic dicarboxylic acid,
a3) 0-5% in moles of units deriving from at least one unsaturated aliphatic dicarboxylic acid;
b) a diol component comprising, with respect to the total diol component:
b1) 95-100% in moles of units deriving from at least one saturated aliphatic diol;
b2) 0-5% in moles of units deriving from at least one unsaturated aliphatic diol;
ii) 30-60% by weight of at least one polyhydroxyalkanoate ii.;
iii) 0.01-5% by weight of at least one cross-linking agent and/or a chain extender iii. comprising at least one compound having di- and/or multiple functional groups comprising isocyanate, peroxide, carbodiimide, isocyanurate, oxazoline, epoxy, anhydride, divinyl ether groups and mixtures thereof;
iv) 0-10% by weight of at least one filler agent;
v) 2-30% by weight of plant fibres.
US Pat. No. 10,595,480

TOMATO LINE PSQ-9Z16-9148

Seminis Vegetable Seeds, ...

1. A tomato plant comprising at least a first set of the chromosomes of tomato line PSQ-9Z16-9148, a sample of seed of said line having been deposited under ATCC Accession Number PTA-125019.
US Pat. No. 10,596,249

TILAPIA VIRUS AND USES THEREOF

KIMRON VETERINARY INSTITU...

1. An isolated polypeptide encoded by the nucleic acid having a sequence selected from the group consisting of SEQ ID NOs: 2-11 or a nucleic acid complementary to a sequence selected from the group consisting of SEQ ID NOs: 2-11.
US Pat. No. 10,597,529

GLASS-FIBRE-REINFORCED POLYCARBONATE MOULDING COMPOSITIONS WITH IMPROVED TOUGHNESS

Covestro Deutschland AG, ...

1. A composition consisting ofA) from 50 to 70 parts by weight of aromatic polycarbonate or polyester carbonate,
B) from 15 to 30 parts by weight of rubber-free vinyl copolymer,
C) from 7-15 parts by weight of organically surface-modified chopped glass fibre,
D) from 1 to 8 parts by weight of a graft polymer with an elastomeric graft base, wherein the graft base consists of acrylate rubber,
E) from 0.1 to 10_parts by weight of additives,
where the sum of the parts by weight of components A) to E) in the composition is standardized to 100,
wherein
(i) a size composed of an organic compound or a mixture of various organic compounds is used as surface-modification of the glass fibre at a concentration such that the carbon content of component C is from 0.2 to 2% by weight,
(ii) the ratio of the integrated peak area of the FTIR spectrum in the wave number range from 2700 to 3000 cm?1 to the integrated peak area of the FTIR spectrum in the wave number range from 500 to 4000 cm?1, in each case measured on the dichloromethane-extracted content of this size of component C, is from 0.20 to 0.70.
US Pat. No. 10,600,604

PHOSPHOR COMPOSITIONS AND LIGHTING APPARATUS THEREOF

CURRENT LIGHTING SOLUTION...

1. A phosphor composition comprising a solid solution of aluminum nitride and a complex oxide comprising europium and strontium, wherein an amount of oxygen in the solid solution is at least 0.4 weight percent and less than 1 weight percent.
US Pat. No. 10,595,481

TOMATO LINE PSQ-9Z16-9141

Seminis Vegetable Seeds, ...

1. A tomato plant comprising at least a first set of the chromosomes of tomato line PSQ-9Z16-9141, a sample of seed of said line having been deposited under ATCC Accession Number PTA-125022.
US Pat. No. 10,596,250

METHODS OF TREATING AND PREVENTING INFLUENZA INFECTIONS

Longhorn Vaccines and Dia...

1. A method of treating, preventing, or inhibiting symptoms of an influenza virus infection comprising:providing an immunogenic preparation that contains at least two peptides, wherein at least one of the two peptides comprises an amino acid sequence that is at least 95% identical to any one of SEQ ID NOs: 6, 14-17, 47, and 54-55; and at least one of the two peptides comprises a T-cell stimulating epitope; and
administering the immunogenic preparation to a patient to generate an immunological response to the infection.
US Pat. No. 10,595,482

TOMATO LINE CHIHE14-1119

Seminis Vegetable Seeds, ...

1. A tomato plant comprising at least a first set of the chromosomes of tomato line CHIHE14-1119, a sample of seed of said line having been deposited under ATCC Accession Number PTA-123668.
US Pat. No. 10,596,251

NANOEMULSION RESPIRATORY SYNCYTIAL VIRUS (RSV) SUBUNIT VACCINE

NanoBio Corporation, Ann...

1. A method for inducing an increased level of acquired immunity against diseases caused by respiratory syncytial viruses (RSV) comprising:(a) administering to a subject a first effective amount of a vaccine comprising:
(i) at least one isolated RSV antigen, wherein the isolated RSV antigen is an isolated RSV F protein, an isolated RSV G protein, an isolated antigenic fragment of RSV F protein, an isolated antigenic fragment of RSV G protein, or any combination thereof;
(ii) an immune-enhancing nanoemulsion or a dilution thereof, comprising droplets having an average size of about 1000 nm or less, an aqueous phase, at least one oil, at least one surfactant, and at least one organic solvent, wherein the at least one isolated RSV antigen is comprised within the nanoemulsion; and
(b) administering to the subject a second boost amount of the same vaccine, wherein the level of acquired immunity is increased as compared to a subject that has not been administered the nanoemulsion.
US Pat. No. 10,597,531

ELECTRICALLY CONDUCTIVE PARTICLE FOAMS BASED ON THERMOPLASTIC ELASTOMERS

BASF SE, Ludwigshafen (D...

1. Foam beads comprising: a base which comprises a thermoplastic elastomer; and a coating provided on a surface of the base, the coating essentially consisting of at least one electrically conductive substance,wherein a proportion of a total of the at least one electrically conductive substance ranges from 0.1 to 1 wt %, based on the foam beads.
US Pat. No. 10,595,483

COTTON VARIETY SICOT 754B3F

COMMONWEALTH SCIENTIFIC A...

1. A plant of the cotton (Gossypium hirsutum) variety Sicot 754B3F, or a plant part comprising a cell, tissue or organ thereof, wherein representative seed of variety Sicot 754B3F have been deposited under ATCC Accession Number PTA-126054.
US Pat. No. 10,597,532

POLYESTER POLYOLS AND METHODS OF MAKING AND USING THE SAME

Elevance Renewable Scienc...

1. A block copolymer, comprising a first block and a second block, wherein the first block is formed from a polyester polyol;wherein the polyester polyol comprises constitutional units formed from (a) short-chain diols and (b) diacids or esters thereof;
wherein the diacids or esters thereof are selected from the group consisting of 1,18-octadecanedioic acid, 1,20-eicosanedioic acid, and any esters thereof;
wherein the short-chain diols are selected from the group consisting of diethylene glycol, triethylene glycol, tetraethylene glycol, pentaethylene glycol, dipropylene glycol, tripropylene glycol, and tetrapropylene glycol; and
wherein the weight-to-weight ratio of the 1,18-octadecanedioic acid, or esters thereof, to dibasic acids having fewer than 18 carbon atoms, or esters thereof, is at least 20:1.
US Pat. No. 10,595,484

OMEGA-3 RICH HIGH YIELDING CULTIVAR OF PERILLA FRUTESCENS ‘CAP HEMA’

CENTRE FOR AROMATIC PLANS...

1. A new and distinct Perilla frutescens cultivar ‘CAP HEMA’ representative seeds of which are deposited at NCIMB, UK under accession number NCIMB 42768.
US Pat. No. 10,596,253

VACCINES AGAINST GENITAL HERPES SIMPLEX INFECTIONS

Board of Supervisors of L...

1. A vaccine comprising a recombinant herpes simplex virus (HSV), wherein the recombinant HSV comprises a recombinant HSV genome comprising:(a) a modified UL53 gene comprising a deletion corresponding to the region of the UL53 gene that encodes amino acids 31-68 of wild-type gK;
(b) a modified UL20 gene comprising a deletion corresponding to the region of the UL20 gene that encodes amino acids 4-22 of wild-type UL20 protein; and
(c) a gene encoding a foreign antigen;wherein the recombinant HSV is capable of replication in a host cell and incapable of entry into axonal compartments of neurons.
US Pat. No. 10,597,533

SOLAR CELL MODULES WITH IMPROVED BACKSHEET

Performance Materials NA,...

1. A backsheet for a photovoltaic module, the backsheet comprising an outer skin, a core, and an inner skin, wherein the outer skin comprises a polyamide-ionomer blend composition consisting essentially of:(i) a polymer component consisting essentially of:
1) 53 to 64 weight %, based on the combination of (1) and (2), of a polyamide component selected from the group consisting of PA-6, PA-11, PA-12, and combinations thereof;
2) 36 to 47 weight %, based on the combination of (1) and (2), of at least one ionomer, wherein each of the at least one ionomer component comprises a copolymer of
(a) ethylene;
(b) from 5 weight % to 15 weight % of an alpha, beta-unsaturated carboxylic acid selected from the group consisting of acrylic acid and methacrylic acid;
(c) from 0.5 weight % to 12 weight % of at least one comonomer that is an ethylenically unsaturated dicarboxylic acid or derivative thereof selected from the group consisting of maleic acid, fumaric acid, itaconic acid, maleic anhydride, and a C1-C4 alkyl half ester of maleic acid; and
(d) from 0 weight % to 30 weight % of monomers selected from alkyl acrylate or alkyl methacrylate;
wherein the alkyl groups have from one to twelve carbon atoms; wherein the weight percentages of the alpha, beta-unsaturated C3-C8 carboxylic acid, the at least one comonomers, and the alkyl acrylate or alkyl methacrylate are based on the total weight of the copolymer; and wherein the carboxylic acid functionalities are at least partially neutralized to form carboxylate salts comprising zinc cations;
(ii) 0 to 20 weight % of a pigment having a refractive index greater than 1.8;
(iii) 8 to 40 weight % of a filler having a refractive index of 1.6 or less; wherein the sum of the weight percentages of the pigment and the filler is from 8 to 50weight %; and
(iv) 0.1 to 5 weight % of weathering additives selected from oxidation inhibitors, UV stabilizers and hindered amine light stabilizers; wherein the weight percentages of the pigment, the filler, and the weathering additives are based on the total weight of the composition.
US Pat. No. 10,595,485

SOYBEAN CULTIVAR S170044

M.S. Technologies, L.L.C....

1. A plant of soybean cultivar S170044, representative seed of said soybean cultivar having been deposited under ATCC Accession No. PTA-125430.
US Pat. No. 10,596,254

SYNTHETIC CONJUGATE OF CPG DNA AND T-HELP/CTL PEPTIDE

City of Hope, Duarte, CA...

1. A method of increasing the effectiveness of an antigenic peptide CTL epitope vaccine component, the method comprises conjugating a fusion peptide to a DNA oligomer, wherein the fusion peptide comprises a T-help epitope and an antigenic peptide CTL epitope, wherein the antigenic peptide CTL epitope is conjugated to the DNA oligomer, and wherein the antigenic peptide CTL epitope is amino acid residues 14-32 of SEQ ID NO:3 or amino acid residues 14-32 of SEQ ID NO:4.
US Pat. No. 10,596,766

METHOD FOR WELDING A POLYOLEFIN PLASTIC AND A PLASTIC BASED ON A POLYMER CONTAINING CARBONYL GROUPS

1. A method for welding a polyolefin plastics material that has a first joining zone to a plastics material based on at least one polymer which contains carbonyl groups that has a second joining zone, using a primer, the method comprising:providing the polyolefin plastics material,
providing the plastics material based on at least one polymer which contains carbonyl groups,
preheating the first joining zone of the polyolefin plastics material,
applying the primer to the preheated first joining zone,
bringing the first joining zone provided with the primer into contact with the second joining zone of the plastics material based on at least one polymer which contains carbonyl groups, and
integrally bonding the first joining zone to the second joining zone
wherein the primer contains, based on the polymer proportion of said primer, at least 20 wt. % of at least one polymer that comprises maleic acid anhydride units or maleic acid anhydride derivative units.
US Pat. No. 10,597,534

CHEMICALLY RESISTANT THERMOPLASTIC COMPOSITIONS

DSM IP ASSETS B.V., Heer...

1. A thermoplastic composition comprising:a) a polyamide component comprising at least three amide monomer units, wherein the polyamide component comprises:
(i) from 20 to 60 wt. %, relative to total weight of the polyamide component a), at least one aliphatic polyamide comprising at least one aliphatic monomer unit of the at least three amide monomer units having a carbon to nitrogen ratio (C/N) equal to 7 or above, and
(ii) from 40 to 80 wt. %, relative to the total weight of the polyamide component a), of at least one semi-crystalline semi-aromatic polyamide comprising at least two semi-crystalline semi-aromatic amide monomer units of the at least three amide monomer units and being selected from the group consisting of PA4T/6T and PA4T/6T/66 having a melting temperature of at least 290° C. as measured by DSC at a heating rate of 10° C./min according to standard ISO 11357-3 (2009); and
(b) a stabilizer system comprising elemental iron particles and a copper salt, wherein
the composition exhibits, after 1024 hours of immersion in a water based H2SO4 solution at pH1 at 100° C., a tensile strength retention of 32% and above, and an elongation at break (Eab) of 60% and above.
US Pat. No. 10,595,486

SOYBEAN CULTIVAR 80330329

M.S. Technologies, L.L.C....

1. A plant of soybean cultivar 80330329, representative seed of said soybean cultivar having been deposited under NCMA Accession No. 201910009.
US Pat. No. 10,596,255

SELECTIVELY ALTERING MICROBIOTA FOR IMMUNE MODULATION

SNIPR Technologies Limite...

1. A method of treating or reducing the symptoms of a lung disease or lung condition associated with pathogenic host cells in a human or animal subject, the method comprising selective targeting of the pathogenic host cells, wherein the host cells are Escherichia coli, Actinobacillus, Diplococcus, Staphylococcus, Streptococcus, Mycobacterium, Chlamydia, Klebsiella, Legionella, Haemophilus, Ruminococcus, Veillonella, Acinetobacter, Prevotella, Yersinia, Achromobacter, Burkholderia, Bordetella, Carnobacterium, Alloiococcus, Enterococcus, Bavariicoccus, Vagococcus, or Pseudomonas cells, wherein the host cells are comprised by a microbiota in the subject, wherein the method comprising:a. contacting the microbiota with an engineered nucleic acid sequence for producing a host modifying (HM) crRNA, and
b. producing the HM-crRNA in a host cell, wherein the HM-crRNA is operable with a Cas nuclease in the host cell to form a HM-CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas system, and wherein the HM-crRNA comprises a sequence that is capable of hybridizing to a target sequence of the host cell to guide the Cas nuclease to the target sequence in the host cell, whereby the target sequence is modified by the HM/CRISPR/Cas system and the host cell is killed or growth of the host cell is reduced, thereby reducing the proportion of host cells in the microbiota; and
wherein the microbiota is a lung microbiota.
US Pat. No. 10,597,535

BITUMEN/POLYMER COMPOSITION HAVING IMPROVED MECHANICAL PROPERTIES

TOTAL MARKETING SERVICES,...

1. Bitumen/polymer composition comprising:bitumen,
from 2.5% to 15% by weight of at least one elastomer relative to the total weight of the composition, and
from 0.15% to 2% by weight, relative to the total weight of the composition, of at least one olefinic polymer chosen from random or block terpolymers of ethylene, of a monomer A selected from vinyl acetate and C1 to C6 alkyl acrylates or methacrylates and of a monomer B selected from glycidyl acrylate and glycidyl methacrylate, comprising from 0.5% to 40% by weight of units resulting from the monomer A and from 0.5% to 15% by weight of units resulting from the monomer B, the remainder being formed of units resulting from the ethylene,
wherein:
the elastomer is selected from thermally crosslinkable block copolymers of formula S-B1-B2, in which S represents a monovinylaromatic hydrocarbon block having a peak molecular weight of from 10 000 to 25 000, B1 is a polybutadiene block having a vinyl content of less than or equal to 15 mole percent, B2 is a polybutadiene block having a vinyl content of greater than or equal to 25 mole percent, the B1/B2 weight ratio is greater than or equal to 1:1, and in which the S-B1-B2 block copolymer has a peak molecular weight of from 40 000 to 200 000;
the elastomer comprises at least one thermally crosslinkable block copolymer corresponding to the formula (S-B1-B2)nX in which each S represents a monovinylaromatic hydrocarbon block having a peak molecular weight of from 10 000 to 25 000, each B1 represents a polybutadiene block having a vinyl content of less than or equal to 15 mole percent, each B2 represents a polybutadiene block having a vinyl content of greater than or equal to 25 mole percent, n is an integer ranging from 2 to 6, and X is the residue of a coupling agent, in which the B1/B2 weight ratio is greater than or equal to 1:1, and the (S-B1-B2)nX block copolymer has a peak molecular weight which is from 1.5 to 6.0 times the peak molecular weight of the S-B1-B2 block copolymer;
the S-B1-B2/(S-B1-B2)nX weight ratio is greater than or equal to 1:1;
the elastomer/adjuvant weight ratio in the composition ranges from 15/1 to 2/1; and
said composition having a maximum elongation at break at 5° C., measured according to standard EN 13587, superior or equal to 500%, said composition having a penetrability variation, after 3 days of storage at 180° C., inferior or equal to 5 1/10 mm, the penetrability being measured at 25° C. according to standard EN 1426, and having a ring and ball temperature variation, after 3 days of storage at 180° C., inferior or equal to 5° C., the ring and ball temperature of the composition being measured according to standard EN 1427.
US Pat. No. 10,595,487

LETTUCE VARIETY NUN 00162 LTL

NUNHEMS B.V., Nunhem (NL...

1. A plant, plant part or seed of lettuce variety NUN 00162 LTL, wherein a representative sample of seed of said variety is deposited under Accession Number NCIMB 42805.